CBP / Catenin Signaling Pathway Inhibitors and Their Uses

JP2023517232A5Active Publication Date: 2024-12-0432 PHARMA LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2022554806
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-03-12
Filing Date
2021-03-11
Publication Date
2024-12-04
Estimated Expiration
2041-03-11

AI Technical Summary

Technical Problem

Developing specific small-molecule inhibitors of the CBP/β-catenin interaction that are fully active and bioavailable for therapeutic and cosmetic use has been challenging, hindering their potential in treating conditions mediated by aberrant CBP/β-catenin signaling, such as fibrosis, cancer, and metabolic disorders.

Method used

Synthesis of small molecules, including isoxazole derivatives, that modulate CBP/β-catenin signaling by inhibiting or enhancing p300/β-catenin interactions, formulated into pharmaceutical compositions for therapeutic and cosmetic applications.

Benefits of technology

The synthesized compounds effectively inhibit CBP/β-catenin signaling, demonstrating potent activity in cell-based assays and animal models, offering therapeutic benefits in treating fibrosis, cancer, metabolic disorders, and enhancing vaccine efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Compounds of formula (Ia), (Ib), and (IIa), and pharmaceutically acceptable salts thereof, are provided. Pharmaceutical compositions comprising the compounds are also provided for treating conditions, diseases, or disorders (e.g., fibrosis, cancer, neurological conditions, metabolic disorders (e.g., diabetes, etc.), and skin conditions mediated by abnormal CBP / β-catenin signaling (e.g., dermatitis, psoriasis, scarring, alopecia, etc.). Methods for enhancing vaccine efficacy using the compounds and compositions are also provided. Methods for efficiently synthesizing clinical-grade drugs are also provided, including the use of intermediate 2-propynyl-compounds in the penultimate or final reaction step under GMP conditions to form clinical-grade isoxazole derivatives (e.g., by 3+2 cycloaddition).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Application No. 62 / 988,827 filed March 12, 2020, which is incorporated herein by reference in its entirety.

[0002] Aspects of the present invention generally relate to the modification of the Wnt / β-catenin pathway in mammalian (human and non-human) cells and tissues, more particularly to small molecule inhibitors of CREB-binding protein (CBP) / β-catenin signaling, and more particularly, but not limited to, one or more of metabolic disorders including fibrosis, cancer, neuropathy, diabetes and fatty liver disease (including alcoholic (ALD) and non-alcoholic fatty liver disease (ALD and NAFLD, respectively)), and non-alcoholic fatty liver disease. The present invention relates to remarkably active and bioavailable small molecule CBP / β-catenin inhibitors having broad utility for modulating and treating CBP / β-catenin signaling-mediated conditions and disorders, including (NASH)), skin conditions (e.g., dermatitis, psoriasis, alopecia, aging), wound healing, aging, and possibly one or more of pulmonary hypertension, congestive heart failure, chronic kidney disease, renal fibrosis, endometriosis, cardiac fibrosis, polycystic ovary syndrome (PCOS), and / or systemic fibrosis / scleroderma. Additional embodiments relate to enhancing vaccine efficacy using the disclosed compounds and compositions. [Background technology]

[0003] The evolutionarily conserved Wnt / β-catenin signaling pathway plays a fundamental and essential role in embryonic development and adult homeostasis. Furthermore, given the established and decisive role of dysregulated / hyperfunctional CBP / β-catenin signaling in fibrosis, cancer, neuropathy, skin disorders, and metabolic disorders and aging (including diabetes and fatty liver disease), as well as in other Wnt / β-catenin-mediated conditions and disorders, there has been considerable interest in exploring therapeutic and cosmetic interventions by enhancing p300 / β-catenin signaling, preferably using small molecule inhibitors of CBP / β-catenin interaction that modulate (e.g., inhibit) CBP / β-catenin signaling. However, developing CBP / β-catenin interaction-specific small molecule inhibitors that are sufficiently active and bioavailable (preferably orally available in many cases for therapeutic applications) remains a challenge, substantially hindering the recognition of their therapeutic and functional cosmetic potential to date. Detailed aspects of the present invention provide such compounds, compositions comprising the compounds, pharmaceutical compositions, and methods for synthesizing and using the compounds and compositions therapeutically and cosmetically, as further described below. [Overview of the project]

[0004] Aspects of the present invention can be described in the following section. 1. Equation (Ia): [ka] {In the formula, R a is hydrogen or -CH3; R b This is a monocyclic aryl group having 5 to 7 ring members, which may have 1 to 2 heteroatoms selected from nitrogen, oxygen, or sulfur, and may have one or more substituents selected from the group consisting of halides, cyanos, and lower alkyls; R is a phenyl group; a substituted phenyl group having one or more substituents (the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C 1-4 alkylamino, C 1-4 dialkylamino, halogen, perfluoro C 1-4 alkyl, C 1-4 alkyl, C 1-3 alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups); a benzyl group; a substituted benzyl group having one or more substituents (the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C 1-4 alkylamino, C 1-4 dialkylamino, halogen, perfluoro C 1-4 alkyl, C 1-3 alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups); or a bicyclic aryl group, or a substituted bicyclic aryl having 8 to 11 ring members and optionally having 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur (the substituted bicyclic aryl ring may have one or more substituents independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C 1-4 alkylamino, C 1-4 dialkylamino, halogen, perfluoro C 1-4 alkyl, C 1-3 alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups); R 2 is hydrogen, or -CH3; Y is selected from hydrogen, deuterium, or halogen; W is hydrogen, phosphate or phosphate ester, alkyl acid or fatty acid ester, or X, and X is

Chemical formula

[0005] 2. Alkyl acids or fatty acid esters, [ka] (In the formula, m is between 1 and 14.) [ka] A compound selected from the compounds listed in item 1.

[0006] 3. The compound according to item 1 or 2, wherein R is a bicyclic aryl selected from naphthyl, quinolinyl, isoquinolinyl, quinoxaline, phthalazine, quinazoline, cinnoline, or naphthyridine, or substituted variants thereof.

[0007] 4. The compound is of formula (Ib): [ka] A compound according to any one of the following three items, wherein X1 and X2 are independently selected from N or -CH.

[0008] 5. L is -CH2-; Q is [ka] The compound described in section 4, wherein A, B, and D are independently selected from O, S, N, or -CH. 6. A is -CH, B is N, D is O (Q is Z3-isoxazole-), W is hydrogen, phosphate or phosphate, alkyl acid or fatty acid ester, or X, where X is [ka] The compound described in item 5, selected from [wherein Z is OR4 (wherein R4 is hydrogen or a C1-C6 alkyl group), or Z is an amino acid or an amino acid ester, and n is 1 or 2].

[0009] 7. The compound according to Section 6, wherein Z3 is selected from aryl or heteroaryl, each of which is substituted with 0 to 4 substituents independently selected from hydrogen, deuterium, halogen, C1-C4 alkyl, C1-C3 haloalkyl, -OH, -OC1-C6 alkyl, -OC1-C6 alkyl-C(O)NH-OH, -NH2, -C(O)NH-C1-C6 alkyl-heteroaryl, -NHC(O)C1-C6 alkyl-C(O)NH-OH, heteroaryl, cycloalkyl, heterocycloalkyl, or nitrogen-bonded cycloalkyl or heterocycloalkyl, -NHC1-C4 alkyl, or -N(C1-C4 alkyl)2. 8. The compound according to item 7, wherein Z3 is substituted with 0 to 4 substituents independently selected from hydrogen, deuterium, halogen, C1-C4 alkyl, C1-C3 haloalkyl, -OH, -OC1-C6 alkyl, or nitrogen-bonded heterocycloalkyl, selected from aryl or heteroaryl groups.

[0010] 9. The compound, [ka] TIFF2023517232000012.tif229150 The compound described in item 8, which is TIFF2023517232000013.tif117170.

[0011] 10. A composition or pharmaceutical composition comprising a compound described in any one of paragraphs 1 to 9, and a pharmaceutically acceptable carrier. 11. A method for treating a disease or disorder, comprising the step of administering to a patient or warm-blooded mammal having a disease or disorder mediated by abnormal CREB-binding protein (CBP) / β-catenin signaling in an amount sufficient to inhibit and / or enhance p300 / catenin-mediated signaling in any one of the compounds described in any one of the paragraphs 1 to 10.

[0012] 12. The method according to claim 11, wherein the amount of compound administered includes a therapeutically effective dose. 13. In the compound, W is X, and X is [ka] The method according to claim 11 or 12, wherein Z is selected from OR4 (wherein R4 is hydrogen or a C1-C6 alkyl group), or Z is an amino acid or an amino acid ester, and n is 1 or 2.

[0013] 14. In the compound, X is [ka] The method according to any one of claims 11 to 13, wherein Z is OR4 (wherein R4 is hydrogen or a C1-C6 alkyl group), or Z is an amino acid or ester and n is 1 or 2.

[0014] 15. The method described in any one of paragraphs 11 to 14, wherein the disease or disorder includes one or more of the following: fibrosis, cancer, neurological conditions, metabolic disorders, and skin conditions. 16. The method according to paragraph 15, wherein the metabolic disorder includes one or more of diabetes mellitus and / or fatty liver disease. 17. The method according to paragraph 16, wherein the fatty liver disease includes one or more of alcoholic fatty liver (ALD), non-alcoholic fatty liver (NAFLD), and / or non-alcoholic steatohepatitis (NASH).

[0015] 18. The method according to paragraph 15, wherein the fibrosis is pulmonary, hepatic, renal, cardiac, endometrial, cutaneous, or systemic fibrosis. 19. The method described in paragraph 18, wherein fibrosis includes fibrosis in the tissue of a SARS-CoV-2 (COVID-19) patient. 20. The method of paragraph 15, comprising the step of administering a CBP / β-catenin antagonist in combination with, or as adjunct to, one or more immunotherapies, including cytotoxic and / or targeted chemotherapy, and / or radiotherapy, and / or checkpoint inhibitors (e.g., anti-PD1, anti-PD-L1, or anti-CTLA4), chimeric antigen receptor (CAR-T) and / or CAR-NK cell-based therapies, in order to treat cancer. 21. The method according to paragraph 15, wherein the neurological condition includes one or more of Huntington's disease (HD), Parkinson's disease (PD), Alzheimer's disease (AD), multiple sclerosis (MS), and / or amyotrophic lateral sclerosis (ALS), muscular dystrophy (MD), and / or spinal muscular atrophy (SMA).

[0016] 22. The method according to paragraph 15, wherein the skin condition includes one or more of the following: atopic dermatitis, psoriasis, acne, fibrosis, wounds, scars, burns, sun or UV damage, diabetic ulcer formation, chronic ulcer formation, and / or alopecia. 23. The method according to claim 22, wherein W is an alkyl acid or fatty acid ester, and the administration includes topical administration. 24. A cosmetic method for treating a skin condition, comprising the step of administering a cosmetically effective amount of a compound described in any one of paragraphs 1 to 10 to a patient or warm-blooded mammal having a skin condition, wherein W is an ester of an alkyl acid or fatty acid, and the administration includes topical administration. 25. The method according to paragraph 24, comprising one or more aging skin conditions selected from among wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of vibrance, loss of elasticity, thinning, scarring, acne, sun damage, hair loss, loss of hair color, reduced cuticle growth, and reduced nail growth. 26. A method for efficiently synthesizing a clinical-grade drug, comprising the use of an intermediate 2-propynyl compound in the second to last or last reaction step, under GMP conditions, to form a clinical-grade isoxazole derivative by 3+2 cycloaddition. 27. In the step of preparing a clinical-grade isoxazole derivative, in the second to last or final reaction step, the final pharmaceutically acceptable salt, phosphate or phosphate of formula (IIa): [ka] {In the formula, R a is hydrogen or -CH3; R b This is a monocyclic aryl group having 5 to 7 ring members, which may have 1 to 2 heteroatoms selected from nitrogen, oxygen, or sulfur, and may have one or more substituents selected from the group consisting of halides, cyanos, and lower alkyls; R is a phenyl group; a substituted phenyl group having one or more substituents (one or more substituents may be amino, amidino, guanidino, hydrazino, amidazonyl, C 1-4 Alkylamino, C 1-4 Dialkylamino, halogen, perfluoroC 1-4 Alkyl, C 1-4 Alkyl, C 1-3 A group independently selected from one or more of the alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups); a benzyl group; a substituted benzyl group having one or more substituents (one or more substituents may be amino, amidino, guanidino, hydrazino, amidazonyl, C 1-4 Alkylamino, C 1-4 Dialkylamino, halogen, perfluoroC 1-4 Alkyl, C 1-3A bicyclic aryl group having 8 to 11 ring members and possibly 1 to 3 heteroatoms selected from nitrogen, oxygen, or sulfur; R 2 is hydrogen, or -CH3; Y is selected from hydrogen, deuterium, or halogen; W is hydrogen, an alkyl acid or fatty acid ester, or X, where X is [ka] The method of claim 26, comprising the step of preparing a compound by the method of any one of claims 6 to 9 using the steps described above, prior to any arbitrary formation of the intermediate 2-propynyl compound of [wherein Z is selected from OR4 (wherein R4 is hydrogen or C1-C6 alkyl), or Z is an amino acid or amino acid ester, and n is 1 or 2].

[0017] 28. The method according to paragraph 26 or 27, wherein the last or second to last step, carried out under GMP conditions, is preceded by one or more reaction steps under non-GMP conditions as part of an overall reaction scheme for preparing a clinical-grade isoxazole derivative.

[0018] 29.Formula (IIa): [ka] {In the formula, R a is methyl or hydrogen; R b This is a monocyclic aryl group having 5 to 7 ring members, which may have 1 to 2 heteroatoms selected from nitrogen, oxygen, or sulfur, and may have one or more substituents selected from the group consisting of halides, cyanos, and lower alkyls; R is a phenyl group; a substituted phenyl group having one or more substituents (one or more substituents may be amino, amidino, guanidino, hydrazino, amidazonyl, C 1-4 Alkylamino, C 1-4 Dialkylamino, halogen, perfluoroC 1-4 Alkyl, C 1-4 Alkyl, C 1-3 A group independently selected from one or more of the alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups); a benzyl group; a substituted benzyl group having one or more substituents (one or more substituents may be amino, amidino, guanidino, hydrazino, amidazonyl, C 1-4 Alkylamino, C 1-4 Dialkylamino, halogen, perfluoroC 1-4 Alkyl, C 1-3 A bicyclic aryl group having 8 to 11 ring members and possibly 1 to 3 heteroatoms selected from nitrogen, oxygen, or sulfur; R 2 is hydrogen, or -CH3; Y is selected from hydrogen, deuterium, or halogen; W is X, and X is [ka] A compound selected from [wherein Z is OR4 (wherein R4 is hydrogen or C1-C6 alkyl), or Z is an amino acid or amino acid ester, and n is 1 or 2].

[0019] 30. A method for enhancing vaccine efficacy, comprising the step of administering to a subject an amount of the compound according to any one of claims 1 to 10 that is sufficient to inhibit and / or enhance CBP / β-catenin-mediated signaling and / or p300 / catenin-mediated signaling before and / or during and / or after vaccination.

[0020] 31. The method according to claim 31, wherein the amount of compound administered comprises a therapeutically effective amount. 32. The method according to claim 30 or 31, wherein enhancing vaccine efficacy includes one or more of the following: an increase in the level of vaccine antigen-specific antibodies; an increase in the percentage of protection produced; an increase in the number and / or persistence of differentiated memory T cells; and / or an increase in the duration of protection. 33. The method according to any one of claims 30 to 32, comprising inhibiting CBP / β-catenin-mediated signaling and / or enhancing p300 / catenin-mediated signaling, thereby maintaining the asymmetric metabolism of post-mitotic cells in activated T cells in a subject; enhancing antigen-specific immunity by increasing the number and / or persistence of differentiated memory T cells; and / or enhancing the presentation of antigens to T cells by antigen-presenting cells to enhance cooperation between the innate and adaptive immune systems.

[0021] 34. The method according to any one of claims 30 to 33, wherein the vaccination comprises the administration of an antiviral vaccine. 35. The method according to any one of claims 30 to 34, wherein the vaccination comprises administering an antiviral vaccine selected from influenza, SARS, SARS-CoV-2, HPV-A, HPV-B, and / or herpes zoster. 36. The method according to any one of claims 30 to 35, wherein the subject is a human being whose age is 55 to 75 years, 55 to 85 years, ≥ 50 years, ≥ 60 years, or ≥ 65 years.

[0022] 37. The method according to any one of claims 30 to 36, wherein the administration includes administration as an initiator before vaccination; and / or administration concurrently with vaccination; and / or administration or concurrent administration after the first vaccination. [Brief explanation of the drawing]

[0023] [Figure 1] This figure shows the results of a luciferase assay based on SuperTOPFLASH cells (Wnt-driven luciferase activity in a stably transfected cell line, Hek293, STF1.1) compared to ICG-001, a specific CBP / β-catenin inhibitor recognized in the art, using a positive control (at 1.25, 2.5, 5, and 10 μM) for three exemplary isoxazole compounds of the present invention (encoded [3+2]-101, [3+2]-117, and [3+2]-229; each compared at concentrations between 16 and 1000 nM), according to an unspecified embodiment of the present invention. As is readily apparent, the three isoxazole compounds of the present invention generally exhibit approximately 10× or more potency than that of the control compound ICG-001 in this assay. [Figure 2] According to an additional non-limiting aspect of the present invention, the results of a Survivin promoter-driven luciferase activity assay (assay of human Survivin 1Kb-promoter-driven luciferase activity in a stably transfected Hek293 cell line; 1Kb Hu-Survivin / luc-Hek293) comparing the CBP / β-catenin inhibitory activity of three exemplary isoxazole compounds of the present invention (encoded [3+2]-101, [3+2]-117, and [3+2]-229; each compared at concentrations between 0.1 and 10 μM) with the art-approved specific CBP / β-catenin inhibitor ICG-001 (at 1.25, 2.5, 5, and 10 μM) are shown. As is readily apparent, the three isoxazole compounds of the present invention generally have IC50 values ​​that are at least approximately 10 × or more potent than those of the control compound ICG-001 in this assay. [Figure 3A-3B] According to a further additional, non-limiting aspect of the present invention, the results of a SYBR-Green qPCR assay for survivin / BIRC5 (CBP-specific) and EphB2 (p300-specific) gene expression are shown using GAPDH as a control gene. Figure 3A compares compound [3+2]-101 of the present invention (at 1 μM) with the art-recognized positive control ICG-001 (at 10 μM) in inhibiting the expression of the CBP / β-catenin-specific gene (H. Ma et al Oncogene 2005, 24,3619-31) survivin / Birc5 gene (reflected as an increase in ΔΔCt). As is readily apparent, the CBP / β-catenin expression inhibitory activity of the isoxazole of the present invention is approximately 10 × greater than that of the control. Figure 3B compares the compound [3+2]-101 of the present invention (at 1 μM) with the art-recognized positive control ICG-001 (at 10 μM) in stimulating EphB2 (p300 / β-catenin-specific gene (Kumar S, et. al. Cancer Res. 2009, 69,3736-45) gene expression (reflected as a decrease in ΔΔCt). As is readily apparent, the EphB2 gene expression stimulating activity of the isoxazole of the present invention is at least 10 × greater than that of the control. This reflects a decrease in CBP / β-catenin-based transcription accompanied by an increase in p300 / β-catenin-based transcription, mediated by the specific CBP / β-catenin inhibitory activity of [3+2]-101 and ICG-001. [Figure 4A-4B]According to a further non-limiting aspect of the present invention, to further confirm that ICG-001 and [3+2]-117 selectively inhibit β-catenin binding to CBP (Figure 4A) while enhancing β-catenin binding to p300 (Figure 4B), the immunoprecipitation assay performed in SW480 colorectal cancer cells (Emami K. et al. PNAS USA, 2004 Aug 24;101(34):12682-7) as described above is shown. Immunoprecipitation of β-catenin by CBP was inhibited by ICG-001 at 10 μM (Figure 3A) and by [3+2]-117 at 500 nM. The activity of [3+2]-117 was approximately 20-fold more than that of ICG-001 (comparing lane 1 (DMSO control) to lanes 2 and 3). Despite the high homology between CBP and p300, the minimal interaction between β-catenin and p300 in SW480 cells was not blocked by ICG-001. Indeed, treatment with 10 μM ICG-001 slightly increased the amount of β-catenin immunoprecipitated with p300, consistent with a switch from CBP / β-catenin-mediated transcription to p300 / β-catenin-mediated transcription associated with the initiation of differentiation (Figure 4B, p300 IP, compare lanes 1 and 2). [3+2]-117 at 500 nM dramatically increased the interaction of β-catenin with p300 (Figure 4B, p300 IP, compare lanes 1 and 3). Quantification of immunoblot data based on pixelation is shown below the immunoblot. [Figure 5] A further non-limiting aspect of the present invention is shown in this figure, which illustrates a significant increase in body weight (Bonferroni multiple comparison study; mean + / -SD) in mice treated with [3+2]-120A and mice treated with [3+2]-120B in a bleomycin-induced pulmonary fibrosis model study in mice (treatment period: days 7-20). [Figure 6]According to a further non-limiting aspect of the present invention, in the experiment shown in Figure 5, all mice survived (therefore, survival curves for different treatment groups are overwritten; log-rank test), whereas conventionally, approximately 30% of mice die before day 21 even when treated in this bleomycin-induced pulmonary fibrosis model. [Figures 7A-7D] According to a further non-limiting aspect of the present invention, Figures 5 and 6 show, based on histological analysis, that in the present study, there was a significant (Bonferroni multiple comparison study; mean + / -SD) reduction in lung mass and Ashcroft score in mice treated with [3+2]-120A and [3+2]-120B. Figures 7A to 7D are as follows: body weight on the day of slaughter (7A); left lung mass (7B); post-caval lobe mass (7C); and Ashcroft score (7D). [Figures 8A-8E] According to a further non-limiting aspect of the present invention, Figures 5-7 show representative histological data for the tests (micrographs of Masson's trichrome-stained lung sections; first magnification ×100) and illustrate that the [3+2] series compounds are effective in reducing extracellular collagen deposition in a bleomycin-induced pulmonary fibrosis model. Figures 8A-8E are as follows: historical bleomycin-only control (8A, "ID:103"); [3+2]-120A low dose (8B, "ID:102"); [3+2]-120A high dose (8C, "ID:201"); [3+2]-120B low dose (8D, "ID:302"); and [3+2]-120B high dose (8E, "ID:401"). [Figure 9] A further non-limiting aspect of the present invention is shown in this figure, demonstrating the safety of the treatment, as there was no significant difference in average body weight on any day during the treatment period between the vehicle group and the treatment group (representative compounds of the present invention [3+2]-121A (low dose) and [3+2]-121B) (high dose compound [3+2]-121A)) in an NG / Nga mouse model of atopic dermatitis. [Figure 10]According to a further non-limiting aspect of the present invention, Figure 9 shows that in the experiment, there was no significant difference in the amount of food consumed per mouse ("food intake") between the vehicle control group and the treatment group. [Figures 11A-11B] According to a further non-limiting aspect of the present invention, Figures 9 and 10 show that in the trials, the [3+2]-121A group (low dose) showed a significant reduction in the total dermatitis severity score, mainly with respect to the back, on days 10 and 14, compared to the vehicle control group. Figures 11A and 11B are as follows: back area (11A); and total volume (back area plus atrial appendage area) (11B). [Figure 12] According to a further non-limiting aspect of the present invention, Figures 9 to 11 show that in the trials, the [3+2]-121A group and the [3+2]-121B group showed a significant decrease in TEWL on day 14, demonstrating an improvement in barrier function. [Figure 13A-13C] According to a further non-limiting aspect of the present invention, the figure shows that representative tissue sections taken in the tests of Figures 9 to 12 confirm a significant reduction in inflammation and inflammatory cell influx in the [3+2]-121A and [3+2]-121B groups, as shown in the representative micrographs. Figures 13A to 13C are as follows: Vehicle control (13A); [3+2]-121A (13B); and [3+2]-121B (13C). [Modes for carrying out the invention]

[0024] Equation (Ia): [ka] [In the formula, R a is hydrogen or -CH3; R b This is a monocyclic aryl group having 5 to 7 ring members, which may have 1 to 2 heteroatoms selected from nitrogen, oxygen, or sulfur, and may have one or more substituents selected from the group consisting of halides, cyanos, and lower alkyls; R is a phenyl group; a substituted phenyl group having one or more substituents (one or more substituents may be amino, amidino, guanidino, hydrazino, amidazonyl, C 1-4 Alkylamino, C 1-4 Dialkylamino, halogen, perfluoroC 1-4 Alkyl, C 1-4 Alkyl, C 1-3 A group independently selected from one or more of the alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups); a benzyl group; a substituted benzyl group having one or more substituents (one or more substituents may be amino, amidino, guanidino, hydrazino, amidazonyl, C 1-4 Alkylamino, C 1-4 Dialkylamino, halogen, perfluoroC 1-4 Alkyl, C 1-3 A group independently selected from one or more of the alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups); or a bicyclic aryl group, or a substituted bicyclic aryl having 8 to 11 ring members and which may have 1 to 3 heteroatoms selected from nitrogen, oxygen, or sulfur (substituted bicyclic aryls include amino, amidino, guanidino, hydrazino, amidazonyl, C 1-4 Alkylamino, C 1-4 Dialkylamino, halogen, perfluoroC 1-4 Alkyl, C 1-3 (It may have one or more substituents independently selected from alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups); R 2 is hydrogen, or -CH3; Y is selected from hydrogen, deuterium, or halogen; W is hydrogen, a phosphate or phosphate, an alkyl acid or fatty acid ester, or X, where X is [ka] [wherein Z is selected from OR4 (wherein R4 is hydrogen or C1-C6 alkyl), or Z is an amino acid or amino acid ester, and n is 1 or 2]; L is -CH2-, -CF2-, or -C(CH3)2-; Q is, [ka] [In the formula, A, B, and D are independently selected from O, S, N, or -CH, and Z1 and Z2 are independently selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OH, and -OC1-C6 alkyl], and [ka] [In the formula, R1, R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, or C1-C6 alkyl containing one or more -OH groups, and Z3 is selected from hydrogen, halogen, or aryl, heteroaryl, cycloalkyl, heterocycloalkyl, or nitrogen-bonded cycloalkyl, heterocycloalkyl, or -NHC1-C4 alkyl, -N(C1-C4 alkyl)2, each of which is hydrogen, deuterium, halogen, C1-C4 alkyl, C1-C3 haloalkyl, -OH, -OC1-C6 alkyl, -OC1-C6 alkyl-C(O)NH-O Compounds of a 5 or 6-membered nitrogen-containing heteroaryl compound substituted with 0 to 2 substituents, selected from H, -NH2, -C(O)NH-C1-C6 alkyl-heteroaryl, -NHC(O)C1-C6 alkyl-C(O)NH-OH, heteroaryl or cycloalkyl, heterocycloalkyl, or nitrogen-bonded cycloalkyl or heterocycloalkyl, -NHC1-C4alkyl, or -N(C1-C4alkyl)2, as well as any salts thereof, including stereoisomers, geometric isomers, tautomers, solvates (e.g., hydrates), metabolites, prodrugs, isotope-labeled derivatives, and pharmaceutically acceptable salts thereof. .

[0025] In this compound, alkyl acids or fatty acid esters are [ka] (In the formula, m is between 1 and 14.) [ka] They can be preferably selected from.

[0026] In this compound, R may be a bicyclic aryl selected from naphthyl, quinolinyl, isoquinolinyl, quinoxaline, phthalazine, quinazoline, cinnoline, naphthyridine, or substituted variants thereof.

[0027] In this compound, preferably, the compound is of formula (Ib): [ka] [wherein X1 and X2 are independently selected from N or -CH].

[0028] In a preferred embodiment of this compound, L is -CH2-; Q is, [ka] {In the formula, A, B, and D are independently selected from O, S, N, or -CH [preferably A is -CH, B is N, D is O (Q is Z3-isoxazole-), W is hydrogen, phosphate or phosphate, alkyl acid or fatty acid ester, or X, where X is, [ka] [wherein Z is selected from OR4 (wherein R4 is hydrogen or C1-C6 alkyl) or Z is an amino acid or amino acid ester, and n is 1 or 2].

[0029] In this compound, Z3 can be selected from aryl or heteroaryl, each of which is substituted with 0 to 4 substituents independently selected from hydrogen, deuterium, halogen, C1-C4 alkyl, C1-C3 haloalkyl, -OH, -OC1-C6 alkyl, -OC1-C6 alkyl-C(O)NH-OH, -NH2, -C(O)NH-C1-C6 alkyl-heteroaryl, -NHC(O)C1-C6 alkyl-C(O)NH-OH, or heteroaryl, cycloalkyl, heterocycloalkyl, or nitrogen-bonded cycloalkyl or heterocycloalkyl, hydrogen, deuterium, halogen, C1-C4 alkyl, C1-C3 haloalkyl, -OH, -OC1-C6 alkyl), or nitrogen-bonded heterocycloalkyl, or -NHC1-C4 alkyl, or -N(C1-C4 alkyl)2 (preferably, Z3 is selected from aryl or heteroaryl).

[0030] Particularly preferred compounds are [ka] TIFF2023517232000030.tif249166 A composition or pharmaceutical composition comprising TIFF2023517232000031.tif244170 and the compounds disclosed herein, and pharmaceutically acceptable excipients or carriers.

[0031] Another aspect of the present invention provides compounds of formulas (Ia), (Ib), and (IIa) that are potent modifiers of the Wnt / β-catenin pathway. Provided are potent compounds that inhibit signaling mediated by CREB-binding protein (CBP) / β-catenin, compositions and pharmaceutical compositions comprising these compounds, and the use of these compounds for the treatment of any abnormal CBP / β-catenin-mediated signaling disorders or disorders, including, but not limited to, fibrosis, cancer, neuropathy, metabolic disorders (including diabetes and fatty liver disease, e.g., alcoholic (ALD) and non-alcoholic fatty liver (ALD and NAFLD, respectively), and non-alcoholic steatohepatitis (NASH)), skin conditions (e.g., dermatitis, psoriasis, alopecia, skin aging, etc.), and possibly one or more of pulmonary hypertension, congestive heart failure, chronic kidney disease, renal fibrosis, cardiac fibrosis, polycystic ovary syndrome (PCOS), endometriosis, and / or systemic fibrosis / scleroderma. Both therapeutic and cosmetic methods are provided.

[0032] The compounds of formulas (Ia), (Ib), and (IIa) of the present invention may contain a chiral center and therefore may exist in different enantiomer and diastereomer forms. The present invention relates to all optical isomers and all stereoisomers of the compounds having the structure defined above, as a racemic mixture and as individual enantiomers and diastereomers of such compounds, and as mixtures thereof, all pharmaceutical compositions and methods of treatment defined below, comprising or using them respectively. In some embodiments, the compound is the (S)-enantiomer. In other embodiments, the compound is the (R)-enantiomer.

[0033] Since the compounds of the present invention may have at least two chiral centers, they can arise in a variety of stereoisomers or configurations. Therefore, the compounds may exist in separated (+)- and (-)-optically active forms, as well as mixtures thereof. The present invention encompasses all such forms within its scope. Individual isomers can be obtained by known methods, such as optical resolution, optically selective reactions, or chromatographic separation in the preparation of the final product or its intermediates. The present invention also provides pharmaceutical compositions and formulations comprising one or more of the disclosed compounds in an amount sufficient to specifically inhibit CBP / catenin-mediated signaling in a warm-blooded mammalian subject when administered to a warm-blooded mammalian subject having a disease or disorder mediated by abnormal CREB-binding protein (CBP) / β-catenin signaling. The amount of compound administered preferably comprises a therapeutically effective amount, in which case the pharmaceutical compositions and formulations may include a therapeutically effective amount of the compound having the structure disclosed herein or a therapeutically acceptable salt thereof and therefor a pharmaceutically acceptable carrier, diluent, or excipient. All of these forms are encompassed within the scope of the present invention.

[0034] definition Unless otherwise specified, "lower" means that a given group has between 1 and 6 carbon atoms. "Halogen" refers to fluorine, chlorine, bromine, or iodine. "Halo" means fluoro, chloro, bromo, or iodine. "Alkyl" refers to a linear, branched, saturated, or aliphatic group that has a chain of carbon atoms. "Alkenyl" refers to a straight or branched carbon chain containing at least one carbon-carbon double bond. "Alkynyl" refers to a linear or branched carbon chain containing at least one carbon-carbon triple bond. Unless otherwise specified, "alkylene" refers to a straight or branched saturated aliphatic polyvalent carbon chain. "Oxy" refers to an -O- group. Note that the oxy group can be further substituted with various substituents to form different oxy groups, including hydroxyl, alkoxy, aryloxy, and heteroaryloxy groups. "Phosphate" or "phosphate salt" refers to PO3H2 or PO3, respectively. -- and appropriate counterions (e.g., 1-2Na) + , 1-2K + , or Ca ++ It means (etc.).

[0035] "Thiole" refers to an -S- group. Note that the thio group can be further substituted with various substituents to form different thio groups, including mercapto, alkylthio, arylthio, and heteroarylthio. "Sulfinyl" refers to the -SO- group. Note that the sulfinyl group can be further substituted with various substituents to form different sulfinyl groups, including alkylsulfinyl, arylsulfinyl, and heteroarylsulfinyl groups. "Sulfonyl" refers to the -SO2- group. Note that the sulfonyl group can be further substituted with various substituents to form different sulfonyl groups, including alkylsulfonyl, arysulfonyl, and heteroarylsulfonyl groups.

[0036] "Alkoxy" refers to an oxygen moiety that has further alkyl substituents. A "heteroatom" refers to an atom that is neither a carbon atom nor a hydrogen atom. Examples of heteroatoms, though not limited to these, include nitrogen, oxygen, and sulfur. "Aryl" refers to a monocyclic or polycyclic group in which each ring is aromatic, or which, when fused with one or more rings, forms an aromatic ring. "Heteroaryl" refers to a monocyclic or polycyclic aromatic group in which at least one ring atom is a heteroatom and the remaining ring atoms are carbon. "Cycloalkyl" refers to a non-aromatic, saturated or partially unsaturated monocyclic, fused bicyclic, or bridging polycyclic ring group.

[0037] "Heterocycloalkyl" means a cycloalkyl as defined herein, wherein one or more of the ring-forming atoms are heteroatoms independently selected from N, O, or S. As used herein, "fused ring" refers to a ring in which, when the ring atoms common to both rings are directly bonded to each other, they are bonded to the other ring to form a compound having a bicyclic structure. As used herein, "bridged ring" refers to a ring in which two ring atoms common to both rings are not directly bonded to each other, but are bonded to the other ring to form a compound having a bicyclic structure. A "protected derivative" refers to a derivative of a compound in which one or more reaction sites are blocked by a protecting group. A comprehensive list of suitable protecting groups can be found in TW Greene, *Protecting Groups in Organic Synthesis*, 3rd edition, John Wiley & Sons, Inc. 1999.

[0038] An "isomer" refers to any compound that has the same molecular formula but differs in the properties or arrangement of the bonds between its atoms, or in the arrangement of its atoms in space. Isomers that differ in the arrangement of their atoms in space are called "stereoisomers." Stereoisomers that are not mirror images of each other are called "diastereomers," and stereoisomers that are mirror images that cannot be superimposed are called "enantiomers" or sometimes "optical isomers." The carbon atoms bonded to the four non-identical substituents are called "chiral centers." A compound with one chiral center has two enantiomers with opposite chirality. A mixture of two enantiomers is called a "racemic mixture." A compound with two or more chiral centers has twon-1 They have enantiomer pairs (where n is the number of chiral centers). Compounds with two or more chiral centers can exist as individual diastereomers or as a mixture of diastereomers, called a “diastereomer mixture.” When one chiral center is present, the stereoisomers can be characterized by the absolute configuration of that chiral center. Absolute configuration refers to the spatial arrangement of substituents attached to the chiral center. Enantiomers are characterized by the absolute configuration of their chiral centers and are described by the R- and S-sequencing rules of Kahn, Ingold, and Prelogue. Conventions for stereochemical nomenclature, methods for determining stereochemistry, and methods for separating stereoisomers are well known in the art (see, for example, “Advanced Organic Chemistry”, 4th edition, March, Jerry, John Wiley & Sons, New York, 1992).

[0039] "Animals" include humans, non-human mammals (e.g., mice, rats, dogs, cats, rabbits, cows, horses, sheep, goats, pigs, deer, etc.), and non-mammals (e.g., birds, etc.). "Disease" includes, in particular, any unhealthy condition or part thereof in an animal, which may be caused by or likely to be caused by a medical or veterinary therapy applied to that animal, i.e., "side effects" of such therapy. "Pharmacologically acceptable" generally means that a substance is useful in preparing a pharmaceutical composition that is safe, non-toxic, non-biological, and not undesirable, and includes substances that are acceptable for veterinary and human pharmaceutical use.

[0040] "Pharmacologically acceptable salt" or "salt" means a salt of the compound of the present invention that is pharmaceutically acceptable and has desirable pharmacological activity, as defined above. Such salts include acid addition salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or acid addition salts formed with organic acids, such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxy These include ethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]octa-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, etc. Pharmaceutically acceptable salts also include base addition salts, which can be formed if the acidic proton present is capable of reacting with an inorganic or organic base. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide, and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, etc.

[0041] "A therapeutically effective dose" means the amount that, when administered to an animal to treat a disease, is sufficient to perform such treatment for the disease. "An effective amount for prevention" means the amount that, when administered to an animal to prevent a disease, is sufficient to provide such prevention for the disease. "Treatment" or "to treat" means any administration of the compounds of the present invention, including (i) preventing disease occurring in animals that are predisposed to disease but have not yet experienced or shown the pathology or symptomatology of the disease; (ii) suppressing disease in animals that have experienced or shown the pathology or symptomatology of the diseased area (i.e., halting further development of the pathology and / or symptomatology); or (iii) relieving disease in animals that have experienced or shown the pathology or symptomatology of the diseased area (i.e., reversing the pathology and / or symptomatology).

[0042] "Cosmetically effective amount" is an amount that, when administered (e.g., transdermally or topically), is sufficient to affect the cosmetic treatment of a cosmetic condition (e.g., wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of color, loss of elasticity, thinning hair, scarring, acne, sun damage, hair loss, loss of hair color, reduced cuticle growth, reduced nail growth).

[0043] Therapeutic Uses and Pharmaceutical Compositions of the Compounds of the Present Invention According to aspects of the present invention, the exemplary diseases and conditions discussed below can be treated by modulating a common pathway shared by the disease (WNT-β-catenin signaling), regardless of the causative or tissue in which they manifest. For example, treating a disease or disorder may include administering an amount of the compound of the present invention sufficient to inhibit CBP / catenin signaling and / or enhance p300 / catenin-mediated signaling to a patient or warm-blooded mammal with a disease or disorder mediated by abnormal CREB-binding protein (CBP) / β-catenin signaling. The WNT-β-catenin pathway plays a crucial role in a wide range of diseases. Assuming that WNT signaling plays a critical role in virtually every organ system in normal homeostasis and post-injury repair, it is not surprising that abnormal regulation of this signaling cascade is associated with a range of diseases (see, e.g., Kahn, M., NATURE REVIEWS | DRUG DISCOVERY VOLUME 13 | JULY 2014 | 513). Beyond its clear role in multiple malignancies, abnormal WNT signaling is involved as a significant component in a variety of other diseases, including neurological disorders, inflammatory and fibrous diseases, and disorders of endocrine function and bone metabolism in adults.

[0044] In more detail, abnormal WNT signaling is associated with the involvement of cancer stem cells in minimal residual disease in cancers (e.g., solid tumors (e.g., colon, pancreas, lung, liver, bladder, prostate, melanoma, glioma, medulloblastoma, osteosarcoma, uterus, endometrium, and breast, etc.) and humoral tumors (e.g., CML, CLL, AML, ALL, etc.); multiple myeloma; autoimmune disorders including type 1 diabetes, rheumatoid arthritis, and inflammatory bowel disease; focal disorders (e.g., psoriasis, vitiligo, and atopic dermatitis); cardiac, hepatic, lung, and renal fibrosis, including systemic and peritoneal fibrosis (endometriosis), and ocular fibrosis. Fibrosis; osteoarthritis and osteoporosis; metabolic diseases including type II diabetes mellitus; hypertension; familial adenomatous polyposis; myelodysplastic syndromes (MDS); myeloproliferative neoplasms (MPN); CHIP (clonal hematopoiesis with undetermined potential); prefibrotic conditions (e.g., AFLD, NASH, NAFLD, cirrhosis); polycystic kidney disease; polycystic ovary syndrome (PCOS), endometriosis, metabolic diseases; type II diabetes mellitus; hypertension; lung disorders (e.g., asthma and COPD); neurological disorders including neurogenesis, autism, spectrum disorders, and schizophrenia, and neurodegenerative diseases including ALS, Huntington's disease, Parkinson's disease, Alzheimer's disease, frontotemporal dementia, and multiple sclerosis (MS); and more generally, conditions associated with aging. The involvement of WNT signaling in specific representative diseases is outlined below in detail.

[0045] Cancer. Abnormal regulation of WNT signaling has emerged as a recurring theme in cancer biology. The components of WNT signaling can be basically characterized as positive or negative components; negative components, which primarily act to suppress tumorigenesis, are found in mutated or loss-of-function states in cancer, while positive components are activated. The 1991 discovery that mutations in the tumor suppressor APC were associated with the majority of sporadic colorectal cancers through abnormal activation of WNT signaling demonstrated considerable momentum for attempting to therapeutically target this pathway. Germline deficiencies in APC lead to familial adenomatous polyposis, in which affected individuals develop hundreds of polyps in the colon at a young age, eventually progressing to colorectal cancer with 100% penetrant. Loss of function in both alleles of APC is required for tumorigenesis and, in relation to the protein's ability, regulates the stability of the β-catenin protein as well as chromosomal stability. APC is now attracting attention as the most frequently mutated gene overall in human cancers. Mutations affecting the WNT pathway are not limited to colon cancer. For example, loss-of-function mutations in AXIN have been found in hepatocellular carcinoma, and oncogenic β-catenin mutations, first described in colon cancer and melanoma, have since been found to occur in a variety of solid tumors, including hepatocellular carcinoma, thyroid tumors, and ovarian endometrioid adenocarcinoma. Epigenetic silencing is also frequently observed to alter the expression levels of negative regulators of the WNT-β-catenin pathway. For example, methylation of genes encoding putative extracellular WNT antagonists, such as secreted Frizzled-related proteins (SFRPs), has been described in colon, breast, prostate, lung, and other cancers. Increased expression of WNT ligands or effector proteins, including Disabled (DVL), has also been described.In particular, abnormal WNT signaling is linked to cancer stem cells involved in minimal residual disease (MRP) and recurrence of solid tumors (e.g., colon, pancreas, lung, liver, bladder, prostate, melanoma, glioma, medulloblastoma, osteosarcoma, uterus, endometrium, and breast) as well as humoral tumors (e.g., CML, CLL, AML, ALL). Specific small molecule CBP / β-catenin antagonists are effective in eliminating cancer stem cells, MRP, and disease recurrence (e.g., Kim, et al. Exp. Hematol. 2017 doi: 10.1016 / j.exphem.2017.04.010). Furthermore, Barrett's esophagus, which is pre-malignant and syndromeal, such as clonal hematopoiesis (CHIP), myelodysplastic syndrome (MDS), myelofibrosis (MF), and myeloproliferative neoplasm (MPN) with undetermined potential, and is driven by deficient stem cells, can be prophylactically removed with specific small molecule CBP / β-catenin antagonists (Thomas and Kahn Cell Biol. Toxicol. 2016 doi: 10:1007 / s10565-016-9318-0).

[0046] Fibrosis. Fibrosis is characterized by the excessive accumulation of extracellular matrix components that disrupt the construction of physiological tissues, leading to dysfunction of affected organs. Generally, fibrosis is suggested to account for approximately 45% of deaths in developed industrial countries, highlighting the great medical need for effective anti-fibrotic therapies. Activated WNT-β-catenin signaling is linked to fibrosis in numerous organ systems, including the lungs, and this developmental pathway has been shown to be reactivated in adult tissues after injury. Specific small molecule WNT modification has been proven highly effective in several mouse models of fibrosis (e.g., lung and kidney models).Specific inhibition of the CBP-β-catenin interaction has been shown to not only alleviate but also reverse late fibrotic injury in mouse models of the lung, kidney, liver, heart, systemic fibrosis, and endometriosis (Sci Rep. 2019 Dec 27;9(1):20056. doi:10.1038 / s41598-019-56302-4; Akcora et al., Biochim Biophys Acta Mol Basis Dis. 2018 Mar;1864(3):804-818. doi: 10.1016 / j.bbadis.2017.12.001; Xiao et al., Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1313-1322. doi: 10.1016 / j.bbadis.2019.01.027. Epub 2019 Jan 30;Zhao et al., Sci Rep. 2018 Jun 12;8(1):8996. doi:10.1038 / s41598-018-27064-2; Kimura et al., EBioMedicine 2017 Sep;23:79-87. doi: 10.1016 / j.ebiom.2017.08.016. Epub 2017 Aug 19. Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP / β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial). In this trial, 10 and 40 mg / m² were administered. 2 The CBP / β-catenin antagonist PRI-724, administered intravenously at a daily dose for 12 weeks (1 week on, 1 week off) to patients with HCV cirrhosis, appeared safe, provided dose-dependent plasma exposure to the drug, and resulted in improvements in liver tissue features and Child-Pugh classification in several patients.

[0047] Pulmonary fibrosis. Pulmonary fibrosis destroys the lungs' ability to transport oxygen and other gases into or outside the bloodstream. The disease alters the delicate and elastic tissue of the lungs, transforming these tissues into thicker, harder fibrous tissue. This alteration or replacement of the original tissue is similar to permanent scarring that can occur in other damaged tissues. Scarring in the lungs reduces the lungs' ability to bring gases (i.e., oxygen and carbon dioxide) into or outside the bloodstream. Gradually, the alveolar sacs are replaced by fibrotic tissue. Where scarring forms, the tissue thickens, causing an irreversible loss of the tissue's ability to transport oxygen into the bloodstream. Symptoms include, in particular, shortness of breath with exertion; chronic dry cough; fatigue and weakness; chest discomfort; loss of appetite; and rapid weight loss. Several causes of pulmonary fibrosis are known, and they include occupational exposure and environmental exposure. Many jobs, especially those involving mining or where workers are exposed to asbestos or metal dust, can cause pulmonary fibrosis. Workers performing these types of jobs may inhale small particles (such as silica dust or asbestos fibers) that can damage the lungs, particularly the peripheral airways and alveolar sacs, leading to scarring associated with fibrosis. Agricultural workers are also at risk. Certain organic substances, such as moldy hay, can trigger an allergic reaction in the lungs. This reaction, known as farmer's lung, can cause pulmonary fibrosis. Other gases found on farms are directly toxic to the lungs. Another cause is sarcoidosis, a disease characterized by the formation of granulomas (areas of inflammatory cells), which can attack any part of the body but most frequently affect the lungs. Some medications, such as radiation therapy for breast cancer, can have undesirable side effects that can cause pulmonary fibrosis. Connective tissue or collagen diseases, such as systemic sclerosis, are also associated with pulmonary fibrosis. Genetic or familial factors may be involved, but these causes are less common than the other causes listed above. In chronic obstructive pulmonary disease (COPD), connective tissue proliferation and fibrosis may be characteristic of severe COPD. COPD can develop as a result of smoking or chronic asthma.

[0048] Idiopathic pulmonary fibrosis (IPF). When all known causes of interstitial lung disease have been ruled out, the condition is called "idiopathic" pulmonary fibrosis (IPF). More than 83,000 Americans live with IPF, and more than 31,000 new cases occur each year. Scarring of the lungs is involved in this debilitating condition. The pulmonary sacs develop scarring, or fibrotic tissue, which gradually interferes with the body's ability to move oxygen into the bloodstream, preventing essential organs and tissues from receiving enough oxygen to function properly. There are several potential causes of IPF, including viral diseases, such as SARS-CoV-2, and allergies or environmental exposure (including cigarette smoke). There is also a familial form of the disease, known as familial idiopathic pulmonary fibrosis. Patients with IPF suffer from symptoms similar to those of patients with pulmonary fibrosis, as their lungs lose the ability to move oxygen into the bloodstream. These symptoms include, in particular, shortness of breath during or after physical activity; spasmodic, dry cough; gradual, unintentional weight loss; fatigue and weakness; chest discomfort; and clubbing or swelling of the fingertips (or occasionally the toes) due to tissue accumulation. These symptoms can greatly reduce the quality of life for patients with IPF. Pulmonary rehabilitation and oxygen therapy can reduce the lifestyle-altering effects of IPF, but they do not result in a cure.

[0049] Diabetes and metabolic diseases. WNT signaling is crucial not only in the maintenance, differentiation, and migration of stem cells but also in organogenesis. WNT signaling also plays a critical role in various endocrine functions and is therefore linked to several endocrine disorders. WNT signaling is important in the regulation of insulin sensitivity, and its dysregulation is linked to the development of diabetes. In particular, WNT10B increases insulin sensitivity in skeletal muscle cells. Overexpression of WNT5B induces adipogenesis. Decreased expression of β-catenin-independent WNT5B, demonstrated in patients with type 2 diabetes, can increase susceptibility to type 2 diabetes. β-catenin / TCF7L2-dependent WNT signaling (standard pathway) is involved in pancreatic development, islet function, and insulin production and secretion. Glucagon-like peptide (GLP-1) and chemokine instrom cell-derived factor-1 (SDF1) modify standard WNT signaling. Furthermore, polymorphisms in the transcription factor TCF7L2 (also known as TCF4) are associated with increased susceptibility to type 2 diabetes. Individuals with the TCF7L2 risk allele exhibit impaired insulin secretion, suggesting that TCF7L2 in pancreatic β-cells plays a crucial role in glucose metabolism through the regulation of pancreatic β-cell volume.

[0050] Experimental loss of TCF7L2 function in pancreatic islets impairs glucose-stimulated insulin secretion, suggesting that disruption in the Wnt signaling pathway may substantially contribute to susceptibility to T2D and its pathogenesis. Interestingly, nicotine has been shown to partially enhance renal cell proliferation and fibronectin production under high glucose conditions by activating the Wnt / β-catenin pathway. Increased Wnt / CBP / β-catenin signaling may initially induce pancreatic β-cell proliferation; however, continuous Wnt-driven pro-mitotic signaling may ultimately lead to loss of differentiation potential and functionality.

[0051] Recently, researchers treated untreated human pancreatic islets from cadavers with a condition medium derived from constitutively generated WNT3A L-cells, R-spondin 3, and noggin, and then added RHO-related protein kinase (ROCK) and RHOA inhibitors to enhance cell viability. This resulted in an approximately 20-fold increase in β-cell proliferation compared to glucose alone. Importantly, treatment with this condition medium did not impair glucose-stimulated insulin secretion or reduce cellular insulin content. Transcriptome-wide gene expression profiling and follow-up signaling studies demonstrated that the condition medium treatment specifically promoted WNT signaling.

[0052] Neurological disorders. The importance of WNT signaling during embryonic development of the central nervous system is well established. The WNT pathway also regulates neural patterning and neural plasticity. WNT also plays a role in axonal guidance and influencing synapse formation. Therefore, it is not surprising that abnormalities in WNT signaling are observed in neurological disorders in adulthood. For example, a certain Scottish family with a high incidence of schizophrenia, depression, and bipolar disorder was found to possess a balanced chromosomal translocation involving the DISC1 gene (which is disrupted in schizophrenia 1). Subsequently, the protein product of DISC1 was found to play a crucial role in neurogenesis and neural progenitor cell proliferation. DISC1 directly interacts with GSK3β activity, inhibiting it and thus enhancing β-catenin-mediated transcription.

[0053] Neuroanatomical observations and functional magnetic resonance imaging (MRI) have shown that a major pathological feature in individuals with autism may be premature overgrowth of the cerebral cortex, hippocampus, amygdala, and cerebellum. Interestingly, transgenic mice expressing a constitutively active form of β-catenin in neuronal progenitor cells developed macroscopically hypertrophied cerebral cortex, hippocampus, and amygdala. Importantly, variations in copy number of microdeletions and microduplications of genes involved in the standard WNT signaling pathway (e.g., Frizzled 9 (FZD9), B-cell lymphoma 9 (BCL9), or cadherin 8 (CDH8)) are found in patients with autism spectrum disorder. Relevant studies investigating dedicators of WNT2, DISC1, MET, cytokinesis protein 4 (DOCK4), or Abelson helper integration site 1 (AHI1; also known as jouberin) have shown further evidence that the standard WNT pathway may be affected in autism.

[0054] The WNT signaling cascade is also linked to Alzheimer's disease. Presenilin protein, associated with early-onset Alzheimer's disease, is a negative regulator of standard WNT signaling. Atypical alleles of the WNT receptor LRP6 (low-density lipoprotein receptor-associated protein 6) are associated with Alzheimer's disease in population-based linkage analysis. This suggests that multiple mechanisms resulting from WNT-mediated regulation in adult neurogenesis may be associated with Alzheimer's disease. Because the underlying causes (one or more) of Alzheimer's disease remain unclear, the mechanisms by which abnormal WNT regulation may play a role in Alzheimer's disease are also unknown. WNT signaling is involved in cerebral angiogenesis and blood-brain barrier formation, synapse formation, amyloid-β-induced neuroinflammation and neurotoxicity, and neurodegeneration. Abnormal regulation of any or all of these processes may contribute to disease onset and progression. Skin. The WNT signaling cascade is linked to skin development and maintenance (see, e.g., STEM CELLS 2018;36:22-35). Secreted Wnt proteins can act as growth factors, stimulating multiple intracellular signaling pathways and regulating a variety of processes, including cell proliferation, differentiation, migration, and polarity. Among the Wnt-stimulated pathways, Wnt / β-catenin signaling is particularly known as a crucial regulatory pathway governing fate selection during development and tissue morphogenesis. Wnt signaling is one of the main signals that direct skin development and maintenance. While Wnt signaling is primarily linked to HF (hair follicle) induction during skin development, it has also recently been shown to regulate epidermal lamination. In primary human keratinocytes, Wnt5a acts as an autocrine stimulant, promoting extracellular calcium-induced keratinocyte differentiation by coupling with the Wnt / β-catenin pathway. Throughout life, the skin epidermis is regularly regenerated. Self-regenerating and differentiating, epidermal cytoplasmic cells (SCs) provide an unlimited source of cells to maintain tissue homeostasis, as well as regenerate HFs and repair the epidermis after injury. Wnt signaling plays a crucial role in all of these processes, with Wnt-dependent signaling being critical in the maintenance, activation, and fate determination of the SC population.

[0055] Strengthening vaccines (e.g., SARS-CoV-2 (COVID-19), influenza, etc.) Age. With age, the immune system loses some of its strength (immunosening, reflected in fewer naive T cells and B cells), which may contribute to greater vulnerability to COVID-19 and, more generally, to infection in older subjects (e.g., ≥60 or ≥65 years in humans). Furthermore, vaccines may perform poorly in this elderly population, which often experiences inflammatory senescence (Willyard, C., Nature Vol. 586, 2020; Akbar & Gilroy, Science 369 (6501), 256-257, 2020, DOI: 10.1126 / science.abb0762; A. Parmigiani et al., PLOS ONE 8, e79816 (2013)), characterized by chronic inflammation (impaired clearance of dead and dying cells from sites of immune activity, and factors that can inhibit antigen-specific (e.g., antiviral) immunity, such as C-reactive protein (CRP) and cytokines, such as interleukin-6 (IL-6) and IL-8))).

[0056] Current influenza vaccination strategies that prioritize the elderly (55-75 years) have proven less effective than expected in reducing serious morbidity and mortality in this population, suggesting that additional strategies may be needed to enhance the effectiveness of vaccination, which inherently relies on immunological memory (Anderson et al., Ann Intern Med. 2020;172:445-452. doi:10.7326 / M19-3075).

[0057] Similarly, SARS-CoV-2 primarily induces mild to moderate symptoms in younger individuals, but causes severe respiratory illness (coronavirus disease 2019, COVID-19) that leads to devastating morbidity and mortality in older individuals. A key feature of severe illness is hyperproliferative inflammation in the patient's airways (Merad & Martin, Nat. Rev. Immunol. 20, 355, 2020). Memory T cells. A characteristic of the aging immune system is the inability to induce long-life memories (Kim, Chulwoo, et al., Cell Reports 25, 2148-2162, November 20, 2018). Furthermore, promoting the rate of asymmetric cell division (ACD) can improve long-term survival and T cell function, opening up new prospects for vaccination (Borsa, et al., Sci. Immunol. 4, eaav1730 (2019)). Asymmetric cell division has been shown to be responsible for the intergenerational bifurcation of memory T cells and effector cells from a common precursor activated by antigen recognition in association with antigen-presenting cells (Morrot, Alexandre, Ann Transl Med 2017;5(5):121; citing Verbist KC, Guy CS, Milasta S, et al. Metabolic maintenance of cell asymmetry following division in activated T lymphocytes (Nature 2016;532:389-93)). In addition, memory T cells appear to induce cellular heterogeneity using asymmetric cell division when faced with pathogen reloading (Ciocca, Maria, L. et al., The Journal of Immunology, 2012, 188: 4145-4148).

[0058] Current proposed approaches to vaccine augmentation may involve the use of vaccine adjuvants, higher doses of viral antigens, or the identification of drugs that can improve the vaccine response in older populations (e.g., by rejuvenating the immune system). For example, mTOR inhibitors (Mannick, JB et al. Sci. Transl. Med. 10, 449, eaaq1564, 2020) (e.g., RTB101, rapamycin, metformin) have been proposed. Anti-inflammatory drugs (e.g., losmapimod, dexamethasone) and senolytics (e.g., fisetin) have also been proposed to boost immunity.

[0059] However, there is an even more urgent need for more effective compositions and methods to enhance vaccine responses (e.g., antiviral vaccines for influenza, SARS, SARS-CoV-2, HPV, HEP-A, HEP-B, herpes zoster, etc.) by, for example; by maintaining the asymmetric metabolism of post-division cells in activated T cells in the subject; and / or by enhancing antigen-specific immunity by increasing the number and / or persistence of differentiated memory T cells; and / or in particular, in older subjects (e.g., 55-75 years; ≥60 years; ≥65 years), by enhancing antigen presentation to T cells by antigen-presenting cells to enhance cooperation between the innate and adaptive immune systems (Ljungberg, Johanna K. et al, Front. of Immunol. 10;2521, 2019). Treatment of SIVmac251-infected RMs suppressed by CBP / catenin inhibitors (ART) with PRI-724 (a specific CBP / β-catenin inhibitor) has been shown to reduce the proliferation of T memory stem cells (SCMs) and central memory T-cells (CMs) and modify the SCM and CM CD4+ T-cell transcriptomes with respect to the profile of further differentiated memory T-cells, demonstrating that the stem cell pathway of long-lived memory CD4+ T-cells can be pharmacologically modified in vivo, thus establishing a novel strategy to target HIV persistence (Mavigner, M. et al., J. Virol. doi:10.1128 / JVI.01094-19).

[0060] According to detailed aspects of the present invention, there is a need for safe and effective methods (e.g., prophylactic and / or therapeutic) of treatment to target underlying aging mechanisms in roughly the time of "vaccination."

[0061] According to detailed embodiments of the present invention, the disclosed CBP / catenin inhibitors have substantial utility, for example, to enhance vaccination (e.g., antiviral vaccines in the case of influenza, SARS, SARS-CoV-2, HPV-A, HPV-B, herpes zoster, etc.) in elderly subjects (e.g., 55-75 years; ≥60 years; ≥65 years) by maintaining the asymmetric metabolism of post-divided cells in activated T cells in subjects; and / or to enhance antigen-specific immunity by increasing the number and / or persistence of differentiated memory T cells; and / or particularly to enhance antigen presentation to T cells by antigen-presenting cells to enhance cooperation between the innate and adaptive immune systems in elderly subjects (e.g., 55-75 years; ≥60 years; ≥65 years). According to further embodiments, the compound can be administered prophylactically and / or therapeutically, including administration as an initiator before vaccination and / or concurrently with vaccination and / or after initial vaccination or concurrently (e.g., with a vaccine booster). In a further embodiment, the compound can be used to promote vaccination in mammals (e.g., humans) using any vaccine.

[0062] SARS-CoV-2 (COVID-19) causes tissue destruction (lungs, liver, kidneys, heart, etc.) (e.g., pulmonary fibrosis, ARDS). As discussed above, inflammatory senescence has many implications for COVID-19 patients (for example, as discussed previously by Akbar & Gilroy). The accumulation of senescent cells in the airways of aged patients may be involved in the initiation of an inflammatory cascade that can inhibit the T cell response to present virus-infected cells, and massive, isolated inflammation does not explain the devastating tissue destruction observed in the lungs of severely ill COVID-19 patients, suggesting that age-related changes in T cells may play a role in immunopathology. Highly differentiated, senescence-like T lymphocytes accumulate in aged individuals. These senescent T cells, after activation, proliferate and lose the ability to express multiple markers of aging, including DNA damage-associated proteins [e.g., phosphorylated histone H2AX (gH2AX)] and cyclin-dependent kinase inhibitors (e.g., p16INK4A). Yet they remain highly efficient cytotoxic cells, expressing NKRs and capable of killing different cell types expressing NKR ligands, including senescent non-lymphoid cells. Another consequence of inflammation is the induction of NKR ligand expression by cells in the lung, which should become more susceptible to death by infiltrating NKR-expressing T cells (Id).

[0063] Pulmonary fibrosis. Almost all severe COVID-19-related outcomes are characterized by pneumonia, often with ground-glass opacities, and many (about 40%) develop acute respiratory distress syndrome (ARDS). There is concern that some organs, including the lungs, may have long-term post-infection dysfunction, lack of inflammation and resolution (e.g., pulmonary fibrosis, a recognized complication of ARDS). Mechanical ventilation is the most important supportive therapy for patients with ARDS, including those with COVID-19, but it can induce or exacerbate lung injury known as ventilator-induced lung injury (VILI) (Slutsky and Ranieri NEJM 2013). Although the virus is eradicated in patients recovering from COVID-19, removing the cause of lung injury does not essentially prevent the development of progressive, irreversible fibrotic interstitial lung disease. Furthermore, even relatively small, non-progressive fibrosis can result in significant morbidity and mortality in the elderly population of patients with COVID-19, many of whom have pre-existing lung conditions (Bem, Reinout A.; https: / / doi.org / 10.1016 / S2213-2600(20)30222-8). The description of the group most susceptible to fatality from SARS-CoV-2 infection is also highly representative of patients with idiopathic pulmonary fibrosis (IPF). Available or developing anti-fibrotic therapies may have value in preventing severe COVID-19 in patients with IPF, have potential to treat severe COVID-19 in patients without IPF, and may play a role in preventing fibrosis after SARS-CoV-2 infection (George et al, Lancet August 2020).

[0064] Acute lung injury and ARDS are major causes of death in COVID-19. Conventional therapies may be possible with drugs such as pirfenidone and nintedanib, but pirfenidone and nintedanib are currently only available in oral form and therefore cannot be used in patients who are intubated and mechanically ventilated, thereby limiting their use in individuals with severe COVID-19 in the intensive care unit (ICU). Furthermore, pirfenidone is used when the patient has an estimated glomerular filtration rate of 1.73 m³. 2 If the flow rate is less than 30 mL / min, it should be avoided. Furthermore, both pirfenidone and nintedanib may be associated with hepatotoxicity, and liver dysfunction is common in patients infected with SARS-CoV-2. Further uncertainty is that, regarding the speed at which antifibrotic agents act, known drugs may not be of much value in patients who have already missed the opportunity for effective treatment (Id) or who are on mechanical ventilation (ventilated). According to detailed aspects of the present invention, there is a need for a safe and effective method for treating (e.g., prophylactic and / or therapeutic) SARS-CoV-2 (COVID-19) lung tissue destruction (e.g., pulmonary fibrosis, ARDS). As summarized above under "Therapeutic Uses and Pharmaceutical Compositions of the Invention" (pages 29-34), the usefulness of CBP / β-catenin inhibitors for treating aspects of fibrosis is recognized.

[0065] Accordingly, according to detailed embodiments of the present invention, the disclosed CBP / catenin inhibitors have substantial utility, particularly in elderly individuals (e.g., 55-75 years; ≥60 years; ≥65 years), for treating SARS-CoV-2 (COVID-19) tissue (e.g., lungs, liver, etc.) destruction (e.g., pulmonary fibrosis, ARDS) and preventing long-term complications, including both during the acute phase of the disease. According to further embodiments, the compound may be administered prophylactically and / or therapeutically, and in either case, preferably initiated 1-3 weeks prior to or within the first 1-3 weeks, and preferably before or within the first week of ARDS onset.

[0066] Administration: The pharmaceutical compositions of the present invention are formulated to be compatible with their intended route of administration. Examples of routes of administration include parenteral, e.g., oral (e.g., in the form of capsules or tablets), intravenous, intradermal, subcutaneous, inhalation, transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions (e.g., injections) used for parenteral (especially intravenous), intradermal, or subcutaneous application may contain the following components: sterile diluents, e.g., water for injection, physiological saline, fixative oil, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; antimicrobial agents, e.g., benzyl alcohol or methylparaben; antioxidants, e.g., ascorbic acid or sodium bisulfite; chelating agents, e.g., ethylenediaminetetraacetic acid; buffers, e.g., acetic acid, citric acid, or phosphoric acid, and agents for adjusting tonicity, e.g., sodium chloride or dextrose. Furthermore, the pH may be adjusted with an acid or base, e.g., hydrochloric acid or sodium hydroxide. Parenteral preparations can be sealed in ampoules, disposable syringes, or glass or plastic repeat-dose vials.

[0067] Pharmaceutical compositions suitable for use as injections include sterile aqueous solutions (if water-soluble) or dispersions, and sterile powders for the immediate dissolution and preparation of sterile injections or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL® (BASF, Parsippany, NJ), or phosphate-buffered saline (PBS). In all cases, the composition must be sterile and fluid enough to allow for easy syringe use. It must be stable under manufacturing and storage conditions and protected against contamination by microorganisms, such as bacteria and fungi. Carriers may be solvents or dispersion media containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Adequate fluidity can be maintained, for example, by the use of coatings, such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants. Prevention of microbial activity can be achieved with various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal. In many cases, it is preferable to include isotonic agents in the composition, such as sugars, polyhydric alcohols, such as mannitol, sorbitol, and sodium chloride. Long-term absorption of the injectable composition can be achieved by including absorption-delaying agents in the composition, such as aluminum monostearate and gelatin.

[0068] Sterile injectable preparations can be prepared by incorporating the active compound, for example, a compound having general formula (Ia), in the required amount in a suitable solvent containing one or a combination of the components listed above, and then, if necessary, by sterilization filtration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle containing the dispersion medium and other necessary components obtained from those listed above. In the case of sterile powders for the preparation of sterile injectable preparations, preferred methods of preparation are vacuum drying and freeze-drying, which produce the active ingredient powder plus any further desirable components obtained from its pre-sterilized filtered solution.

[0069] Oral compositions generally contain an inert diluent or food carrier. They can be sealed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, lozenges, or capsules. Oral compositions can also be prepared using a fluid carrier for use as an oral rinse, in which case the compound in the fluid carrier is applied orally, topically, coughed up, or swallowed. Pharmaceutically compatible binders and / or adjuvant materials may be included as part of the composition. Tablets, pills, capsules, lozenges, etc., may contain any of the following components or compounds of similar properties: That is, binders such as crystalline cellulose, tragacanth gum, or gelatin; excipients such as starch or lactose; disintegrants such as alginic acid, Primogel, or corn starch; lubricants such as magnesium stearate or Sterotes; flow enhancers such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavoring agents I such as peppermint, methyl salicylate, or orange flavoring.

[0070] For administration by inhalation, the compound is delivered in the form of an aerosol spray by pressure from a container, dispenser, or nebulizer containing a suitable propellant, such as a gas, such as carbon dioxide. Systemic administration may also be by mucosal or percutaneous means. In the case of mucosal or percutaneous administration, a suitable penetrant for penetration into the barrier is used in this formulation. Such penetrants are generally known in the art and include, for example, cleansing agents, bile salts, and fusidic acid derivatives for mucosal administration. Mucosal administration can be achieved by the use of nasal drops or suppositories. In the case of percutaneous administration, the active compound is formulated in the form of an ointment, ointment, gel, or cream, as is generally known in the art.

[0071] This compound can also be prepared in the form of suppositories (e.g., conventional suppository bases, e.g., cocoa butter and other glycerides) or retention enemas for rectal delivery. In detailed embodiments, the active compound is prepared with a controlled-release formulation, including a carrier that protects the compound from rapid elimination from the body, such as an implantable tablet and a microencapsulated delivery system. Biodegradable, biocompatible polymers can be, for example, ethylene vinyl acetate, polyacid anhydride, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparing such formulations are apparent to those skilled in the art. These materials can also be commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposome suspensions can also be used as pharmaceutically acceptable carriers. For ease of administration and uniformity of dosage, it may be advantageous to formulate oral or parenteral compositions in dose unit forms. As used herein, a unit dosage form refers to a physically distinct unit suitable as a unit dose for the subject to be treated; each unit contains a predetermined amount of the active compound calculated to produce a desired therapeutic effect in relation to the required pharmaceutical carrier. The specification of unit dosage forms of the present invention is indicated by and directly depends on the unique characteristics of the active compound, the specific therapeutic effect achieved, and the limitations inherent in the art for formulating such active compounds for the treatment of an individual. For example, in some embodiments, the pharmaceutical compositions of the present invention are suitable for oral administration in unit dosage forms, e.g., tablets or capsules containing about 1 mg to about 10 g of the compound of the present invention. In some other embodiments, the pharmaceutical compositions of the present invention are suitable for intravenous, subcutaneous, or intramuscular injection. A patient may receive, for example, an intravenous, subcutaneous, or intramuscular administration of about 1 μg / kg to about 1 g / kg of the compound of the present invention. Intravenous, subcutaneous, and intramuscular administration can be performed by bolus injection or by continuous infusion over a period of time. Alternatively, the patient may be administered an oral daily dose approximately equal to the parenteral daily dose, with the composition being administered 1 to 4 times per day.

[0072] The compound can be administered intravenously to mammals, including humans, (e.g., by continuous infusion or rapid intravenous administration). In such cases, the dosage can be appropriately selected depending on various factors, such as the patient's weight and / or age, and / or the severity of symptoms and the route of administration. For example, the dosage of a compound for intravenous administration is generally calculated by continuous infusion, based on the human body surface area m². 2 The daily dose is in the range of 1 to 10,000 mg, preferably per human body surface area m². 2 The daily dose is in the range of 1 to 5000 mg, more preferably per square meter of human body surface area. 2 The recommended daily dose is 10 to 5000 mg.

[0073] These medications can be administered according to how often they are administered at specific times per day (once or multiple times per 24 hours), including the time between doses (e.g., every 6 hours), the time when the dose is administered (e.g., at 8 a.m. and 4 p.m. daily), and the amount of medication (e.g., the number of capsules).

[0074] Data-backed examples: Exemplary preparations of exemplary compounds of the present invention are shown in the following representative examples and schemes, and the specific non-limiting data-backed examples of the compounds are intended to illustrate certain exemplary embodiments of the present invention and are not intended in any way to limit the scope of the specification or claims. Compounds of the present invention may also be prepared by the synthetic sequences shown in the following non-limiting examples and schemes. Those skilled in the art will understand that other routes of synthesis may be used similarly. In particular, other routes of synthesis can actually be applied to several embodiments of the present invention. Those skilled in the art will refer to common textbooks, e.g., March's Advanced Organic Chemistry (Michael B. Smith & Jerry March, Wiley-Interscience, 2000), The Practice of Medicinal Chemistry (Camile G. Wermuth, Academia Press, 2003), and Protective Groups in Organic Synthesis (Theosora W. Greene & Peter GM Wuts; John Wiley & Sons Inc, 1999), all of which are incorporated herein by reference with respect to their respective teachings.

[0075] (Example 1) Reagents, synthesis method, and biological property assay used Unless otherwise indicated, all reagents, starting materials, and solvents were obtained from private suppliers and used without further purification. Concentration or evaporation refers to evaporation under reduced pressure using a Buchi rotary evaporator, and / or subsequent evaporation to dryness under high vacuum. The reaction products were purified by silica gel chromatography using the indicated solvent system, or by HPLC purification using a C18 reversed-phase semi-preparative HPLC column with solvent A (0.1% TFA in water) and solvent B (0.1% TFA in CH3CN) as eluents. All final products had a purity of at least 95%, as determined by analytical HPLC analysis with UV detection at 210 nm and / or 254 nm. Reported yields are isolated yields.

[0076] Analytical HPLC analysis was performed using a Phenomenex Luna C18(2) column (3 μm, 150 × 4.6 mm id) on an Agilent 1100 HPLC system with an initial operating pressure in the range of 120–140 bar and a flow rate of 0.6 mL / min, using a binary solvent system A and B. Gradient elution was performed using DMSO-d6 or CDCl3 as an internal standard along with TMS, using a Bruker AV-300 or AV-301 300 MHz NMR spectrometer. A: Milli-Q water containing 0.1% TFA; B: CH3CN containing 0.1% TFA. NMR spectra were recorded using a Bruker AV-300 or AV-301 300 MHz NMR spectrometer, with DMSO-d6 or CDCl3 as an internal standard along with TMS. Mass spectral data were obtained using a Bruker Esquire liquid chromatography-ion trap mass spectrometer.

[0077] The following abbreviations are used in the synthesis examples: aq (aqueous), h (hour), min (minute), sat'd (saturated), THF (tetrahydrofuran), rt (room temperature), Et3N (triethylamine), NaCl (sodium chloride), MgSO4 (magnesium sulfate), CDCl3 (deuterated chloroform), H2O (water), HCl (hydrochloric acid), MeOH (methanol), NaOH (sodium hydroxide), TFA (trifluoroacetic acid), Na2CO3 (sodium carbonate), CH2Cl2 (methylene chloride), EtOAC (ethyl acetate), DMF (dimethylformamide), EtOH (ethanol), DMSO (dimethyl sulfoxide), DMSO-d6 (dimethyl sulfoxide-d6), NaHCO3 (sodium bicarbonate), HPLC (high-performance liquid chromatography), ESI-MS or MS(ESI) (electrospray ionization mass). The following abbreviations are used herein: NMR (nuclear magnetic resonance), DIEA (diisopropylethylamine), brine (saturated NaCl aqueous solution), NH4Cl (ammonium chloride), Boc2O (di-tert-butylcarbonate), HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate), NaI (sodium iodide), KI (potassium iodide), Pd(OAc)2 (palladium(II) acetate), BINAP (2,2'-bis(diphenylphosphin)-1,1'-binaphthyl), DIEA or DIPEA (N,N-diisopropylethylamine), DCC (dicyclohexylcarbodiimide), NCS (N-chlorosuccinimide), PPTS (pyridinium p-toluenesulfonate), and other similar standard abbreviations.

[0078] The biological properties of the exemplary compound of the present invention were determined in at least the following assays. Luciferase assay based on SuperTOPFLASH cells. Hek-293,STF1.1 cells are maintained in Pen-Strep supplemented with DMEM, 10% FBS, and 200 μg / mL G418. The day before the assay, cells are divided into white, opaque 96-well plates at 10,000 cells per well in 50 μL of G418-free complete medium (G418 can be excluded during the screening process if screening for Wnt-signaling inhibitors). After allowing the cells to stabilize and adhere overnight, 40 μL of complete medium (G418-free) containing a 2.5 × final concentration of the compound or DMSO control is added to the cells, and the cells are incubated at 37°C at 5% CO2 for 1 hour before adding 10 μL of 100 mM LiCl solution prepared in the (G418-free) complete medium. After 24 hours, add 100 μL of BrightGlo (Promega, catalog number: G7573) to each well and shake the plate for 5 minutes before reading it with a Perkin-Elmer EnVision plate reader.For example, the day before the assay: Divide the cells into a white opaque 96-well plate with 10,000 cells per well in 50 μL of full growth medium; incubate the plate overnight at 37°C, 25% CO2 to allow the cells to adhere; the next day, prepare the inhibitor to be tested in full growth medium to the desired final concentration of 2.5× (repeat all conditions twice), and add 40 μL of medium containing the compound at a 2.5× concentration to each well (including 2 wells for the stimulation control, 2 wells for the DMSO control, and wells for the positive control ICG-001 (e.g., 2, 5, and 10 micromoles)); after adding all inhibitors and controls, incubate the plate at 37°C, 25% CO2 for 1 hour (while the plate is incubating, prepare fresh 100 mM LiCl in full growth medium); after 1 hour, remove the plate from the incubator and add 100 mM LiCl. Add 10 μL of medium containing LiCl to each well (except for the two unstimulated control wells, to which just 50 microliters of complete medium are added); incubate the plate at 37°C, 5% CO2 for 24 hours; after 24 hours, add 100 microliters of BrightGlo (Promega, catalog number: G7573) to each well, shake the plate for 5 minutes to ensure complete dissolution, and then read the plate with a Perkin-Elmer EnVision 96-well plate reader.

[0079] Assay for human survivin 1Kb-promoter-driven luciferase activity in the stably transfected cell line, 1Kb Hu-survivin-Hek293. Briefly, 1Kb Hu-survivin-Hek293 cells are maintained in DMEM, 10% FBS, Pen-Strep supplemented with 1 μg / mL puromycin. The day before the assay, cells are divided into white, opaque 96-well plates at 10,000 cells per well in 50 μL of complete medium without puromycin (for screening of CBP / β-catenin interaction inhibitors, puromycin can be excluded during the screening process). After the cells are allowed to stand overnight to stabilize and adhere, 50 μL of complete medium (without G418) containing 2× final concentration of the compound or DMSO control is added to the cells. After 24 hours, add 100 μL of BrightGlo (Promega, catalog number: G7573) to each well and shake the plate for 5 minutes before reading it with a Perkin-Elmer EnVision plate reader. For example, the day before the assay, divide the cells into a white opaque 96-well plate with 10,000 cells per well in 50 μL of full growth medium; incubate the plate overnight at 37°C, 25% CO2 to allow the cells to adhere; the next day, prepare the inhibitor to be tested in full growth medium at the desired final concentration of 2× (repeat all conditions twice), add 50 μL of medium containing the compound at 2× concentration to each well (2 wells for the stimulation control, 2 wells for the DMSO control, and one well for the positive control ICG-001 (e.g., containing 2, 5, 10, and 20 μM)); then incubate the plate at 37°C, 25% CO2 for 24 hours; after 24 hours, add 100 μL of BrightGlo (Promega, catalog number: G7573) to each well, shake the plate for 5 minutes to ensure complete lysis, and read with a Perkin-Elmer EnVision 96-well plate reader.

[0080] (Example 2) Synthesis of (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N-(quinoline-5-ylmethyl)propanamide (1) Compound 1, as a pale yellow oily substance, was prepared starting from quinoline-5-carboxyaldehyde, following the procedure disclosed in US7,671,054, as shown in Scheme 1. MS(ESI):m / z494.2(M+H) + . Scheme 1: [ka]

[0081] (Example 3) Synthesis of (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N-(naphthalene-1-ylmethyl)propanamide (2) Compound 2, as a colorless oil, was prepared starting from 1-naphthaldehyde, following the procedure disclosed in US7,671,054, as shown in Scheme 2. MS(ESI):m / z493.3(M+H) + .

[0082] Scheme 2: [ka]

[0083] (Example 4) Synthesis of tert-butyl 2-(2-(benzylcarbamoyl)hydrazinyl)acetate (3) Compound 3 was prepared according to the procedure described in steps 1-3 of Scheme 3 below.

[0084] Scheme 3: [ka] Step 1: tert-butyl 2-(benzylcarbamoyl)hydrazine carboxylate To a solution of tert-butylhydrazine carboxylate (2.5 g, 19 mmol) in dry CH2Cl2 (50 mL) at 0°C, DIEA was added, followed by the dropwise addition of benzyl isocyanate (2.35 mL, 19 mmol). The reaction mixture was stirred overnight under argon at room temperature and then placed in CH2Cl2 (150 mL) and 10% KHSO4 (100 mL). The organic layer was washed with sat'd NaHCO3 (100 mL) and sat'd NaCl (100 mL), dried in (MgSO4), and evaporated to dryness. The title compound (5.4 g) as a white solid was used in the next step without further purification. 1 H-NMR (300 MHz, DMSO-d6) δ 8.54 (br s, 1H), 7.70 (s, 1H), 7.26 (m, 5H), 6.81 (br s, 1H), 4.22 (d, J = 6 Hz, 2H), 1.40 (s, 9H).

[0085] Step 2: N-benzylhydrazine carboxamide 5.4 g of tert-butyl 2-(benzylcarbamoyl)hydrazine carboxylate was treated with CH2Cl2 (50 mL) and TFA (50 mL) under argon at room temperature for 3 hours. The title compound (TFA salt; 5.6 g) was obtained as a pale yellow solid by evaporation to dryness and co-evaporation with CHCl3 twice, and this was used in the next step without further purification. 1 H-NMR (300 MHz, DMSO-d6) δ 7.24 (m, 5H), 7.03 (br s, 1H), 6.82 (br s, 1H), 4.24 (m, 4H). Step 3: tert-butyl 2-(2-(benzylcarbamoyl)hydrazinyl) acetate To a dry CH3CN (38 mL) suspension of N-benzylhydrazine carboxamide (5.6 g), NaHCO3 (4.8 g, 57 mmol), tert-butyl 2-bromoacetate (4.2 mL, 28.5 mmol), and NaI (0.28 g) were added. The reaction mixture was stirred under argon at 60°C for 24 hours and then placed in Depositphotos (100 mL). Insoluble substances were filtered out. The filtrate was washed with water (100 mL). The aqueous layer was further extracted with Depositphotos. The combined organic extracts were dried (Na2SO4) and evaporated to dryness. Purification by silica gel chromatography using Depositphotos / CH2Cl2 (25% and 50%) yielded the title compound (2.3 g) as a white solid. 1 H-NMR (300 MHz, CDCl3) δ 7.30 (m, 5H), 6.38 (br s, 1H), 6.29 (s, 1H), 4.43(d, J = 6 Hz, 2H), 4.11 (t, J = 6 Hz, 1H), 3.42 (d, J = 9 Hz, 2H), 1.47 (s, 9H).

[0086] (Example 5) Synthesis of (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-(propa-2-inyl(ynyl))-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide(4) Compound 4 was prepared according to the procedure described in steps 1 to 4 of Scheme 4 below.

[0087] Scheme 4: [ka]

[0088] Step 1: tert-butyl 2-(2-(benzylcarbamoyl)-1-(propa-2-inyl)hydrazinyl) acetate A mixture of tert-butyl 2-(2-(benzylcarbamoyl)hydrazinyl) acetate (1.0 g, 3.58 mmol), propargyl bromide (0.7 mL, in 9.2 M toluene), NaHCO3 (0.6 g, 7.14 mmol), and KI (60 mg) in dry CH3CN (30 mL) was stirred in a sealed tube at 75°C for 3 days. The reaction mixture was cooled to room temperature and filtered. The filtrate was evaporated and purified by silica gel chromatography using 50% siRNA to obtain the title compound (0.63 g) as a colorless oil. MS(ESI): m / z 318.0(M+H) + ;Analytical HPLC: 17.0min.

[0089] Steps 2-3: (S)-N-benzyl-2-(2-(3-(4-tert-butoxyphenyl)-1-((2,2-diethoxyethyl)(quinoline-5-ylmethyl)amino)-1-oxopropane-2-ylamino)-2-oxoethyl)-2-(propa-2-inyl)hydrazinecarboxamide tert-butyl 2-(2-(benzylcarbamoyl)-1-(propa-2-inyl)hydrazinyl) acetate (0.31 g, 0.98 mmol) was treated with CH2Cl2 (10 mL) and TFA (10 mL) under argon at room temperature for 2 hours. Evaporation to dryness and two co-evaporations with CHCl3 yielded 2-(2-(benzylcarbamoyl)-1-(propa-2-inyl)hydrazinyl)acetic acid (TFA salt) as a yellow oily substance, which was used in the next step without further purification. MS(ESI): m / z 261.9 (M+H) + ;Analytical HPLC: 12.1min.

[0090] To a solution of (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N-(quinoline-5-ylmethyl)propanamide (0.48 g, 0.98 mmol) in DMF (7 mL), DIEA (0.51 mL, 2.93 mmol) and 2-(2-(benzylcarbamoyl)-1-(propa-2-inyl)hydrazinyl)acetic acid (TFA salt) prepared above were added. After cooling to 0°C, HATU (0.37 g, 0.98 mmol) was added. The reaction mixture was stirred under argon at 0°C for 0.5 hours and overnight at room temperature, then placed in ethyl acetate (50 mL) and water (50 mL). The aqueous layer was extracted with ethyl acetate (25 mL x 2), and the combined organic extract was washed with brine (25 mL), dried, (Na2SO4), and evaporated. The desired product (0.79 g) was obtained as a pale yellow foam by silica gel chromatography using 5% MeOH / CH2Cl2. MS(ESI): m / z 737.4(M+H) + ;Analytical HPLC: 16.1min.

[0091] Step 4: (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-(propa-2-inyl)-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide A solution of (S)-N-benzyl-2-(2-(3-(4-tert-butoxyphenyl)-1-((2,2-diethoxyethyl)(quinoline-5-ylmethyl)amino)-1-oxopropane-2-ylamino)-2-oxoethyl)-2-(propa-2-inyl)hydrazinecarboxamide (0.79 g, 1.07 mmol) in formic acid (25 mL) was stirred at room temperature for 20 hours. The solvent was removed, and the resulting residue was placed in ELISA (25 mL) and sat'd NaHCO3 (25 mL). The aqueous layer was further extracted with ELISA (25 mL × 1). The combined organic extract was dried (MgSO4) and evaporated. The crude product was purified by silica gel chromatography using ELISA to obtain the desired product (0.36 g) as a pale yellow foam. MS(ESI): m / z 589.2(M+H)+ ;Analytical HPLC: 12.5min.

[0092] (Example 6) Synthesis of (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-((3-phenylisoxazol-5-yl)methyl)-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide(5) Compound 5 was prepared according to the procedure described in steps 1 to 6 of Scheme 5 below.

[0093] Scheme 5: [ka]

[0094] Steps 1-2: 5-(bromomethyl)-3-phenylisoxazole To a solution of benzaldehyde (2.0 g, 18.8 mmol) in MeOH (18 mL), hydroxylamine hydrochloride (1.6 g, 22.6 mmol) and K2CO3 (3.1 g, 22.6 mmol) were added. The reaction mixture was stirred overnight at room temperature, diluted with water (50 mL), and extracted with RINKAN (50 mL × 1, 25 mL × 2). The organic extract was dried (Na2SO4) and evaporated to dryness. The resulting colorless liquid, benzaldehyde oxime (2.4 g), was used in the next step without further purification. To a mixture of benzaldehyde oxime (2.4 g, 19.4 mmol) in water (60 mL) at room temperature, KCl (1.5 g, 20.1 mmol) and propargyl bromide (5.6 mL, in 9.2 M toluene) were added. The resulting mixture was cooled to 0°C, and oxone (9.2 g, 15 mmol) was added in small increments. The reaction mixture was stirred at 0°C for 1 hour and overnight at room temperature, and extracted with ELISA (50 mL x 2). The organic extract was washed with sat'd NaCl (25 mL), dried (MgSO4), and evaporated to dryness. The title compound (4.2 g) was obtained as a pale yellow solid and was used in the next step without further purification. 1H-NMR (300 MHz, CDCl3) δ 7.80 (m, 2H), 7.47 (m, 3H), 6.63 (s, 1H), 4.52 (s, 2H).

[0095] Step 3: tert-butyl 2-(2-(benzylcarbamoyl)-1-((3-phenylisoxazol-5-yl)methyl)hydrazinyl)acetate A mixture of 5-(bromomethyl)-3-phenylisoxazole (56 mg, 0.24 mmol), tert-butyl 2-(2-(benzylcarbamoyl)hydrazinyl) acetate (60 mg, 0.22 mmol), NaHCO3 (36 mg, 0.43 mmol), and KI (3.7 mg) in 1.5 mL of dry CH3CN was stirred at 65°C for 20 hours. The reaction mixture was cooled to room temperature and filtered. The filtrate was evaporated, and the resulting residue was purified by silica gel chromatography using  / hexane (ratio: 1:1-2:1) to produce the title compound (61 mg) as a white solid. MS(ESI): m / z 437.2(M+H) + .

[0096] Step 4: 2-(2-(benzylcarbamoyl)-1-((3-phenylisooxazol-5-yl)methyl)hydrazinyl)acetic acid 61 mg, 0.14 mmol of tert-butyl 2-(2-(benzylcarbamoyl)-1-((3-phenylisoxazol-5-yl)methyl)hydrazinyl) acetate was treated in CH2Cl2 (1.5 mL) and TFA (1.5 mL) under argon at room temperature for 3 hours. The compound was evaporated to dryness and co-evaporated twice with CHCl3 to dryness, yielding the title compound (TFA salt) as an off-white solid, which was used in the next step without further purification. 1H-NMR (300 MHz, DMSO-d6) δ 7.82 (m, 2H), 7.53 (m, 3H), 7.37 (s, 1H), 7.13 (s, 5H), 7.05 (s, 1H), 6.94 (t, J = 6 Hz, 1H), 4.20 (s, 2H), 4.17 (d, J = 6 Hz, 2H), 3.67 (s, 2H).

[0097] Step 5: (S)-N-benzyl-2-(2-(3-(4-tert-butoxyphenyl)-1-((2,2-diethoxyethyl)(quinoline-5-ylmethyl)amino)-1-oxopropane-2-ylamino)-2-oxoethyl)-2-((3-phenylisoxazol-5-yl)methyl)hydrazinecarboxamide To a solution of (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N-(quinoline-5-ylmethyl)propanamide (69 mg, 0.14 mmol) in DMF (1 mL), DIEA (73 μL, 0.42 mmol) and 2-(2-(benzylcarbamoyl)-1-((3-phenylisoxazol-5-yl)methyl)hydrazinyl)acetic acid (TFA salt; prepared in step 4) were added. After cooling to 0°C, HATU (53 mg, 0.14 mmol) was added. The reaction mixture was stirred under argon at 0°C for 0.5 hours and overnight at room temperature, then added to ethyl acetate (10 mL) and water (10 mL). The aqueous layer was extracted with ethyl acetate (10 mL x 2), and the combined organic extract was washed with brine (10 mL), dried, (Na2SO4) and evaporated. Purification by silica gel chromatography using MeOH / CH2Cl2 (5% and 10%) yielded the desired product (104 mg) as a white foam. MS(ESI): m / z 856.7(M+H) + ;Analytical HPLC: 18.0min.

[0098] Step 6: (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-((3-phenylisoxazol-5-yl)methyl)-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide A solution of (S)-N-benzyl-2-(2-(3-(4-tert-butoxyphenyl)-1-((2,2-diethoxyethyl)(quinoline-5-ylmethyl)amino)-1-oxopropan-2-ylamino)-2-oxoethyl)-2-((3-phenylisoxazol-5-yl)methyl)hydrazinecarboxamide (100 mg) in formic acid (5 mL) was stirred at room temperature for 20 hours. The desired product (67 mg) was obtained as a white solid by evaporation to dryness, purification by silica gel chromatography (CH2Cl2 / CH3OH / NH4OH: 270:9:1 and 180:9:1), and lyophilization. MS(ESI): m / z 708.3(M+H) + HPLC analysis: 14.9 min (>99% purity).

[0099] (Example 7) Synthesis of (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-2-((3-(6-morpholinopyridine-2-yl)isoxazol-5-yl)methyl)-4,7-dioxo-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide (6) Compound 6 was prepared according to the procedure described in steps 1 to 9 of Scheme 6 below.

[0100] Scheme 6: [ka]

[0101] Step 1: 2-Bromo-6-(1,3-Dioxolalan-2-yl)pyridine A reaction mixture of 6-bromopicoline aldehyde (0.4 g, 2.15 mmol), ethylene glycol (0.62 mL, 11.1 mmol), and p-toluenesulfonic acid monohydrate (0.46 g, 2.67 mmol) in 1,2-dichloroethane (14.4 mL) and DMSO (0.32 mL) was stirred overnight at 95 °C under argon, cooled to room temperature, and evaporated to dryness. The resulting residue was diluted with HCl (25 mL), washed with 0.5 N NaOH (20 mL) and sat'd NaCl (15 mL), dried (Na₂SO₄), and evaporated. The crude product was purified by silica gel chromatography (25% HCl / hexane) to obtain the desired product (0.32 g) as a colorless oil. 1 H-NMR (300 MHz, CDCl3) δ 7.61 (t, J = 4 Hz, 1H), 7.51 (m, 2H), 5.83 (s, 1H), 4.21 - 4.07 (m, 4H).

[0102] Step 2: 4-(6-(1,3-dioxolan-2-yl)pyridine-2-yl)morpholine A mixture of 2-bromo-6-(1,3-dioxolan-2-yl)pyridine (0.32 g, 1.38 mmol), morpholine (0.14 mL, 1.65 mmol), Pd(OAc)2 (40 mg), BINAP (104 mg), and Cs2CO3 (0.62 g) in toluene (14 mL) was purged with argon for 2 minutes and then stirred in a sealed tube at 100°C for 22 hours. The reaction mixture was filtered through Celite and evaporated. Purification by silica gel chromatography using 25% and 50% siRNA yielded the title compound (0.26 g) as a brown solid. 1 H-NMR (300 MHz, CDCl3) δ 7.53 (t, J = 4 Hz, 1H), 6.88 (d, J = 4 Hz, 1H), 6..61 (d, J = 6 Hz, 1H), 5.72 (s, 1H), 4.19 - 4.05 (m, 4H), 3.81 (t, J = 4 Hz, 4H), 3.52 (t, H = 4 Hz, 4H).

[0103] Step 3: 6-Morpholinopicolinealdehyde 4-(6-(1,3-dioxolan-2-yl)pyridine-2-yl)morpholine (0.26 g, 1.10 mmol) was suspended in acetone (7 mL) and water (7 mL) to which pyridinium tosylate (83 mg) was added. The reaction mixture was refluxed overnight and concentrated under vacuum. Ether (30 mL) was added, and the mixture was washed with sat'd NaHCO3 (15 mL) and sat'd NaCl (15 mL) and dried to (Na2SO4). Purification by evaporation and silica gel chromatography (25% Ether / hexane) yielded the desired product (0.19 g) as a pale yellow solid. 1 H-NMR (300 MHz, CDCl3) δ 10.1 (s, 1H), 7.71 (t, J = 9, and 4 Hz, 1H), 7.37 (d, J = 9 Hz, 1H), 6..93 (d, J = 6 Hz, 1H), 3.89 (t, J = 4.5 Hz, 4H), 3.68 (t, H = 4.5 Hz, 4H).

[0104] Step 4: 6-Morpholinopicolinealdehyde oxime To a solution of 6-morpholinopicolinaldehyde (0.19 g, 0.99 mmol) in MeOH (18 mL), hydroxylamine hydrochloride (81 mg, 1.17 mmol) and K2CO3 (0.16 g, 1.16 mmol) were added. The reaction mixture was stirred overnight at room temperature, diluted with water (15 mL), and extracted with toluene (10 mL x 3). The organic extract was dried (Na2SO4) and evaporated to dryness. Purification by silica gel chromatography (30% toluene / hexane) yielded the desired product (0.18 g) as a white solid. 1H-NMR (300 MHz, DMSO-d6) δ 11.5 (s, 1H), 7.90 (s, 1H), 7.58 (d, J = 9, and 4 Hz, 1H), 7.08 (d, J = 6 Hz, 1H), 6.81 (d, J = 6 Hz, 1H), 3.70 (t, J = 4.5 Hz, 4H), 3.46 (t, H = 4.5 Hz, 4H).

[0105] Step 5: 4-(6-(5-(bromomethyl)isoxazol-3-yl)pyridine-2-yl)morpholine To a suspension of 6-morpholinopicolinaldehyde oxime (62 mg, 0.30 mmol) in 50% t-BuOH / water (2 mL), chloramine-T trihydrate (88.5 mg, 0.31 mmol), copper(II) sulfate pentahydrate (3 mg), and copper shavings (1 mg) were added, followed by the addition of propargyl bromide (35.9 μL, 9.2 M in toluene). The reaction mixture was stirred overnight at room temperature and then added to HCl (10 mL) and water (10 mL). The aqueous layer was extracted with HCl (10 mL x 2). The combined organic extract was washed with sat'd NaCl (10 mL) and dried to (Na2SO4). Purification by evaporation and silica gel chromatography (25% HCl / hexane) yielded the title compound (34 mg) as a white solid. MS(ESI): m / z 324.0, 326.0 (M+H) + ;Analytical HPLC: 17.8min. Steps 6-9: (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-2-((3-(6-morpholinopyridine-2-yl)isoxazol-5-yl)methyl)-4,7-dioxo-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide. Title compound 6 was obtained by following the procedure described in steps 3-6 of Example 6. MS(ESI):m / z794.4(M+H) + HPLC analysis: 14.1 min (>99% purity).

[0106] (Example 8) Synthesis of (6S,9aS)-N-benzyl-2-((3-(5-fluoropyridine-2-yl)isoxazol-5-yl)methyl)-6-(4-hydroxybenzyl)-4,7-dioxo-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide methanesulfonate (7) Compound 7 was prepared according to the procedure described in steps 1 to 5 of Scheme 7 below.

[0107] Scheme 7: [ka]

[0108] Step 1: 5-Fluoropicolinealdehyde oxime To a solution of 5-fluoropicoline aldehyde (0.5 g, 4.0 mmol) in MeOH (4 mL), hydroxylamine hydrochloride (0.33 g, 4.8 mmol) and K2CO3 (0.67 g, 4.8 mmol) were added. The reaction mixture was stirred overnight at room temperature, diluted with water (10 mL), and extracted with RINKAN (10 mL x 3). The organic extract was dried (Na2SO4) and evaporated to dryness. The title compound (0.52 g) was used as a white solid without further purification in the next step. 1 H-NMR (300 MHz, DMSO-d6) δ 11.7 (s, 1H), 8.59 (d, J = 3 Hz, 1H), 8.09 (s, 1H), 7.87 (m, 1H), 7.77 (m, 1H).

[0109] Step 2: 5-Fluoro-N-hydroxypicolinimidoyl chloride N-chlorosuccinimide (0.42 g, 3.14 mmol) was added to a solution of 5-fluoropicoline aldehyde oxime (0.4 g, 2.85 mmol) in DMF (3 mL). The reaction mixture was stirred overnight at 50°C under argon, cooled to room temperature, and poured into Et2O (15 mL) and water (15 mL). The aqueous layer was extracted with Et2O (15 mL x 2). The organic extract was washed with water (10 mL), sat'd NH4Cl (10 mL), and sat'd NaCl (10 mL), dried (Na2SO4), and evaporated to dryness. The title compound (0.49 g) was used as a white solid without further purification in the next step. 1 H-NMR (300 MHz, DMSO-d6) δ 12.7 (s, 1H), 8.68 (d, J = 2.8 Hz, 1H), 7.96 (m, 1H), 7.84 (m, 1H).

[0110] Step 3: 4-(((6S,9aS)-1-(benzylcarbamoyl)-2-((3-(5-fluoropyridine-2-yl)isoxazol-5-yl)methyl)-4,7-dioxo-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-6-yl)methyl)phenylacetate. To a solution of 4-(((6S,9aS)-1-(benzylcarbamoyl)-4,7-dioxo-2-(propa-2-inyl)-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-6-yl)methyl)phenylacetate (0.60 g, 0.95 mmol; prepared using acetyl chloride instead, according to the procedure disclosed in Example 11) in 27 mL of dry CH2Cl2 at 0°C, 5-fluoro-N-hydroxypicolinimidoyl chloride (0.16 g, 0.90 mmol) was added, followed by the dropwise addition of Et3N (0.25 mL, 1.80 mmol) in 1 mL of CH2Cl2. The reaction mixture was stirred at room temperature under argon at 0°C for 1 hour and 24 hours. The title compound (0.54 g), partially purified as an oily residue, was obtained by evaporation to dryness and purification by silica gel chromatography using CH3OH / CH2Cl2. MS(ESI): m / z 769.3(M+H) + ;Analytical HPLC: 14.9min.

[0111] Step 4: (6S,9aS)-N-benzyl-2-((3-(5-fluoropyridine-2-yl)isoxazol-5-yl)methyl)-6-(4-hydroxybenzyl)-4,7-dioxo-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide A solution of 4-(((6S,9aS)-1-(benzylcarbamoyl)-2-((3-(5-fluoropyridin-2-yl)isoxazol-5-yl)methyl)-4,7-dioxo-8-(quinolin-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl acetate (0.54 g; prepared as shown in Step 3 above) in CH3OH (16 mL) was added dropwise with sat’d NaHCO3 (5.3 mL). The reaction mixture was stirred at room temperature for 3 hours, evaporated in vacuo, and placed in EtOAc (15 mL) and water (15 mL). The aqueous layer was extracted with EtOAc (15 mL × 2). The organic extracts were washed with sat’d NaCl (15 mL), dried (Na2SO4), and evaporated to dryness. Purification by silica gel chromatography using EtOAc / CH2Cl2 afforded the title compound (0.26 g) as a white solid. MS (ESI): m / z 727.3 (M+H) + ; Analytical HPLC: 13.8 min (>96% pure).

[0112] Step 5: (6S,9aS)-N-Benzyl-2-((3-(5-fluoropyridin-2-yl)isoxazol-5-yl)methyl)-6-(4-hydroxybenzyl)-4,7-dioxo-8-(quinolin-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamidomethanesulfonate (6S,9aS)-N-benzyl-2-((3-(5-fluoropyridine-2-yl)isoxazol-5-yl)methyl)-6-(4-hydroxybenzyl)-4,7-dioxo-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide (176 mg, 0.24 mmol) was slowly added to a solution of methanesulfonic acid (23.3 mg, 0.24 mmol) in acetone and CH2Cl2 (6 mL). After stirring at room temperature for several minutes, hexane (approximately 10 mL) was slowly added. The resulting white precipitate was collected by filtration and washed with hexane and ELISA. The desired product (173 mg) was obtained as a pale yellow solid by air drying and freeze-drying with Milli-Q water. MS(ESI): m / z 727.2(M+H) + HPLC analysis: 13.8 min (>97% purity).

[0113] (Example 9) Synthesis of (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-((3-(pyrazine-2-yl)isoxazol-5-yl)methyl)-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide (8) Compound 8 was prepared according to the procedure described in steps 1-2 of Scheme 8 below. Scheme 8: [ka]

[0114] Step 1: N-hydroxypyrazine-2-carbimidoyl chloride The title compound was obtained as a pale yellow solid according to the procedure described in step 2 of Example 8. 1 H-NMR (300 MHz, DMSO-d6) δ 9.10 (s, 1H), 8.77 - 8.73 (m, 3H). Step 2: (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-((3-(pyrazine-2-yl)isoxazol-5-yl)methyl)-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide To a solution of 4-(((6S,9aS)-1-(benzylcarbamoyl)-4,7-dioxo-2-(propa-2-inyl)-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-6-yl)methyl)phenyl acetate (0.30 g, 0.51 mmol) in dry CH2Cl2 (15 mL) at 0°C, N-hydroxypyrazine-2-carbimidoyl chloride (76.1 mg, 0.48 mmol) was added, followed by dropwise addition of Et3N (134 μL, 0.97 mmol). The reaction mixture was stirred at room temperature under argon at 0°C for 1 hour and 20 hours. The title compound (0.12 g) was obtained as a white solid by evaporation to dryness, purification by silica gel chromatography using CH3OH / siRNA, and freeze-drying in CH3CN and Milli-Q water. MS(ESI):m / z710.3(M+H) + HPLC analysis: 12.6 min (>95% purity).

[0115] (Example 10) Synthesis of (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-((3-(pyrrolidine-2-yl)isoxazol-5-yl)methyl)-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide (9) Compound 9 was prepared according to the procedure described in steps 1 to 4 of Scheme 9 below.

[0116] Scheme 9: [ka]

[0117] Steps 1-2: tert-butyl 2-(chloro(hydroxyimino)methyl)pyrrolidine-1-carboxylate The title compound was obtained according to the procedure described in steps 1-2 of Example 8. HPLC analysis: 15.4 min (>97% purity). Step 3: tert-butyl 2-(5-(((6S,9aS)-1-(benzylcarbamoyl)-6-(4-hydroxybenzyl)-4,7-dioxo-8-(quinoline-5-ylmethyl)dihydro-1H-pyrazino[2,1-c][1,2,4]triazine-2(6H,7H,8H,9H,9aH)-yl)methyl)isoxazol-3-yl)pyrrolidine-1-carboxylate (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-(propa-2-inyl)-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide (70 mg, 0.12 mmol) was dissolved in dry CH2Cl2 (5 mL), to which tert-butyl 2-(chloro(hydroxyimino)methyl)pyrrolidine-1-carboxylate (118 mg, 0.48 mmol) was added, followed by dropwise addition of Et3N (0.13 mL, 0.93 mmol). The reaction mixture was stirred under argon at 40°C for 2 days. Purification by evaporation to dryness and silica gel chromatography using ethyl acetate yielded the title compound (26 mg) as a white residue. MS(ESI): m / z 801.5(M+H) + ;Analytical HPLC: 14.7min (94% pure).

[0118] Step 4: (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-((3-(pyrrolidine-2-yl)isoxazol-5-yl)methyl)-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide tert-butyl 2-(5-(((6S,9aS)-1-(benzylcarbamoyl)-6-(4-hydroxybenzyl)-4,7-dioxo-8-(quinoline-5-ylmethyl)dihydro-1H-pyrazino[2,1-c][1,2,4]triazine-2(6H,7H,8H,9H,9aH)-yl)methyl)isoxazol-3-yl)pyrrolidine-1-carboxylate (26 mg, 0.032 mmol) was stirred with CH2Cl2 (1 mL) and TFA (1 mL) under argon at room temperature for 2 hours. The mixture was purified by evaporation to dryness and co-evaporation to dryness twice with CHCl3, and by silica gel chromatography (CH2Cl2 / CH3OH / NH4OH: 180:9:1 and 90:9:1). Subsequently, the desired product (14 mg) was obtained as a white powder by lyophilization with CH3CN and Milli-Q water. MS(ESI):m / z701.3(M+H) + HPLC for analysis: 10.6 min (>99% purity).

[0119] (Example 11) Synthesis of 4-(((6S,9aS)-1-(benzylcarbamoyl)-2-((3-(4-fluorophenyl)isoxazol-5-yl)methyl)-4,7-dioxo-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-6-yl)methyl)phenyl dodecanoate (10) Compound 10 was prepared according to Scheme 10 using the procedure disclosed below. Scheme 10: [ka]

[0120] (6S,9aS)-N-benzyl-2-((3-(4-fluorophenyl)isoxazol-5-yl)methyl)-6-(4-hydroxybenzyl)-4,7-dioxo-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide (1.2 g, 1.67 mmol) was dissolved in dry CH2Cl2 (47 mL) at 0°C. Et3N (0.47 mL, 3.34 mmol) was added, followed by the slow addition of lauroyl chloride (0.58 mL, 2.51 mmol). The reaction mixture was stirred under argon at 0°C for 1 hour and overnight at room temperature, and evaporated to dryness. The resulting residue was placed in HCl (100 mL) and sat'd NaHCO3 (50 mL). The organic layer was washed with sat'd NaCl (50 mL) and dried (MgSO4). Evaporation, purification by silica gel chromatography using HCl / CH2Cl2, and freeze-drying yielded the title product (1.1 g) as a white foam. MS(ESI): m / z 908.7(M+H) + .

[0121] (Example 12) Synthesis of ethyl 2-(2-((4-(((6S,9aS)-1-(benzylcarbamoyl)-4,7-dioxo-2-((3-(pyridine-2-yl)isoxazol-5-yl)methyl)-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-6-yl)methyl)phenoxy)carbonylamino)acetamide)acetate (11) Compound 11 was prepared according to scheme 11 using the procedure disclosed below.

[0122] Scheme 11: [ka]

[0123] Step 1: Ethyl 2-(2-(tert-butoxycarbonylamino)acetamide)acetate A suspension of 2-(2-(tert-Butoxycarbonylamino)acetamido)acetic acid (0.5 g, 2.15 mmol) in CH2Cl2 (8 mL) was added with EtOH (0.14 mL, 2.37 mmol), DCC (0.49 g, 2.37 mmol) and DMAP (29 mg, 0.24 mmol). The reaction mixture was stirred at room temperature overnight under argon and filtered. The filtrate was diluted with CH2Cl2 (25 mL), washed with water (25 mL) and 10% KHSO4 (25 mL), dried (MgSO4) and evaporated. The crude material was purified by silica gel chromatography using EtOAc / hexane to give the title product (0.53 g) as a white oily residue. 1 H-NMR (300 MHz, DMSO-d6) δ 8.17 (t, J = 6 Hz, 1H), 7.0 (t, J = 6 Hz, 1H), 4.09 (q, J = 6 Hz, 2H), 3.82 (d, J = 6 Hz, 2H), 3.56 (d, J = 6 Hz, 2H), 1.38 (s, 9H), 1.16 (t, J = 6 Hz, 3H).

[0124] Step 2: 2-(2-Ethoxy-2-oxoethylamino)-2-oxoethanaminium chloride Ethyl 2-(2-(tert-Butoxycarbonylamino)acetamido)acetate (0.53 g, 2.04 mmol) was treated with 6N HCl (5 mL) in EtOH (5 mL) at room temperature overnight. Removal of all volatiles by evaporation gave the desired product (0.36 g) as a white solid. 1 H-NMR (300 MHz, DMSO-d6) δ 8.84 (br s, 3H), 8.71 (br s, 1H), 4.11 (q, J = 6 Hz, 2H), 3.94 (d, J = 6 Hz, 2H), 3.6 (d, J = 3 Hz, 2H), 1.20 (t, J = 7.5 Hz, 3H).

[0125] Step 3: Ethyl 2-(2-((4-(((6S,9aS)-1-(benzylcarbamoyl)-4,7-dioxo-2-((3-(pyridine-2-yl)isoxazol-5-yl)methyl)-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-6-yl)methyl)phenoxy)carbonylamino)acetamide)acetate (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-((3-(pyridine-2-yl)isoxazol-5-yl)methyl)-8-(quinoline-5-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide (0.13 g, 0.18 mmol) in CH2Cl2 was mixed with diphosgene (31 μL, 0.26 mmol) and DIEA (44.6 μL, 0.26 mmol). The reaction mixture was stirred under argon at room temperature for 2 hours. To this reaction mixture at -5°C, 2-(2-ethoxy-2-oxoethylamino)-2-oxoethaneaminium chloride (0.22, 1.13 mmol), DIEA (0.29 mL, 1.67 mmol), and CH2Cl2 (2.3 mL) were added. The reaction mixture was stirred separately at room temperature under argon for 2 hours before adding Et2O (5 mL). Insoluble substances were removed by filtration. The title product (116 mg) was obtained as a white solid by evaporation to dryness and purification by silica gel chromatography using siRNA / CH3OH. MS(ESI): m / z 895.3(M+H) + .

[0126] (Example 13) Compounds 12-34 shown in Table 1 were prepared using a procedure similar to that used in Examples 6-12, and accordingly using compounds 1-4 exemplified in Examples 2-5 and the starting materials shown in Table 2.

[0127] [Table 1-1] [Table 1-2]

Table 1-3

Table 1-4

Table 1-5

[0128] (Example 14) The starting materials used for the preparation of these examples and the exemplary compounds of the present invention shown in Table 1 are shown in Table 2.

[0129]

Table 2

[0130] (Example 15) Three representative isoxazole compounds ([3+2]-101, [3+2]-117, and [3+2]-229) have generally shown to have approximately 10× or more potency than the positive control compound ICG-001 in a luciferase assay based on SuperTOPFLASH cells approved in the art. Figure 1 shows the results of a luciferase assay (Wnt-driven luciferase activity in stably transfected cell lines, Hek293, STF1.1) using SuperTOPFLASH cells, comparing the CBP / β-catenin inhibitory activity of three exemplary isoxazole compounds of the present invention (encoded [3+2]-101, [3+2]-117, and [3+2]-229; each compared at concentrations between 16 and 1000 nM) with the art-approved CBP / β-catenin inhibitor ICG-001, which was used as a positive control (at 1.25, 2.5, 5, and 10 μM). As is readily apparent, the three representative isoxazole compounds of the present invention exhibit at least approximately 10× or more potency in this assay compared with the control compound ICG-001. The potency of most of the disclosed CBP / β-catenin inhibitor compounds was generally determined to be at least approximately 3X or greater than the potency of the control compound ICG-001 in this assay.

[0131] (Example 16) Three representative isoxazole compounds ([3+2]-101, [3+2]-117, and [3+2]-229) have generally demonstrated approximately 10× or more potency compared to the positive control compound ICG-001 in survivin promoter-driven luciferase activity assays approved in the art.

[0132] Figure 2 shows, according to an additional non-limiting aspect of the present invention, the results of a Survivin promoter-driven luciferase activity assay (assay of human Survivin 1Kb-promoter-driven luciferase activity in a stably transfected Hek293 cell line; 1Kb Hu-Survivin / luc-Hek293) comparing the CBP / β-catenin inhibitory activity of three exemplary isoxazole compounds of the present invention (encoded [3+2]-101, [3+2]-117, and [3+2]-229; each compared at concentrations between 0.1 and 10 μM) with the art-recognized CBP / β-catenin inhibitor ICG-001 (at 1.25, 2.5, 5, and 10 μM) with the CBP / β-catenin inhibitor ICG-001 used as a positive control. As is readily apparent, these three isoxazole compounds of the present invention are IC 50 The IC50 values ​​in this assay are at least approximately 10× or more potent than those of the control compound ICG-001. The IC50 values ​​of most disclosed CBP / β-catenin inhibitor compounds are also shown. 50 The values ​​were generally determined to be at least approximately 3× or more greater than the potency of the control compound ICG-001 in this assay.

[0133] (Example 17) Representative isoxazole compounds [3+2]-101 have generally been shown to have at least approximately 10× or more potency in reducing CBP / β-catenin-based transcription than the positive control compound ICG-001 in the SYBR-Green qPCR assay approved in the art for Survivin / BIRC5.

[0134] According to further additional non-limiting embodiments of the present invention, Figures 3A and 3B show the results of SYBR-Green qPCR assays for the expression of Survivin / BIRC5 (CBP-specific) and EphB2 (p300-specific) genes using GAPDH as a control gene. Figure 3A shows the expression of the CBP / β-catenin-specific gene (H. Ma et al Oncogene 2005, 24,3619-31) and the Survivin / Birc5 gene (ΔΔCt The compound [3+2]-101 of the present invention (at 1 μM) is compared with the art-approved positive control ICG-001 (at 10 μM) in inhibiting (reflected as an increase in) the expression of the isoxazole of the present invention, which is approximately 10 × greater than that of the control. Figure 3B shows the EphB2 (p300 / β-catenin-specific gene (Kumar S, et. al. Cancer Res. 2009, 69, 3736-45) gene expression (ΔΔC). t The compound [3+2]-101 of the present invention (at 1 μM) is compared with the art-approved positive control ICG-001 (at 10 μM) in stimulating EphB2 gene expression (reflected as a decrease in p300 / β-catenin). As is readily apparent, the EphB2 gene expression stimulating activity of a representative isoxazole of the present invention is at least 10 × greater than that of the control. This reflects a decrease in CBP / β-catenin-based transcription, accompanied by an increase in p300 / β-catenin-based transcription, mediated by the specific CBP / β-catenin inhibitory activity of [3+2]-101 and ICG-001.

[0135] (Example 18) Immunoprecipitation assays performed in SW480 cells further confirmed that the positive control compound ICG-001 and the representative compound of the present invention [3+2]-117 selectively inhibit β-catenin from binding to CBP, while enhancing the binding of β-catenin to p300. According to a further non-limiting aspect of the present invention, Figures 4A and 4B show an immunoprecipitation assay performed in SW480 cancer cells, as previously described (Emami K. et al. PNAS USA, 2004 Aug 24;101(34):12682-7), to further confirm that the positive controls ICG-001 and [3+2]-117 selectively inhibit β-catenin binding to CBP (Figure 4A) while enhancing β-catenin binding to p300 (Figure 4B). Immunoprecipitation of β-catenin by CBP was inhibited by ICG-001 at 10 μM (Figure 3A) and by [3+2]-117 at 500 nM. [3+2]-117 showed approximately 20-fold greater activity compared to ICG-001 (comparing lane 1 (DMSO control) to lanes 2 and 3). Despite the high homology between CBP and p300, the minimal interaction between β-catenin and p300 in SW480 cells was not blocked by ICG-001. Indeed, treatment with 10 μM ICG-001 slightly increased the amount of β-catenin immunoprecipitated with p300, consistent with a switch from CBP / β-catenin transcription to p300 / β-catenin transcription associated with the initiation of differentiation (Figure 4B, p300 IP, compare lanes 1 and 2). [3+2]-117 at 500 nM dramatically increased the interaction of β-catenin with p300 (Figure 4B, p300 IP, compare lanes 1 and 3). Quantification of immunoblot data based on pixelation is shown below the immunoblot.

[0136] (Example 19) Using a bleomycin-inducible mouse model of idiopathic pulmonary fibrosis (IPF), we demonstrated the efficacy of representative compounds of the present invention, [3+2]-120A and [3+2]-120B, in a favorable comparison with historical control data for pirfenidone and nintedanib.

[0137] A bleomycin induction model of IPF. As previously demonstrated with first (ICG-001) and second (PRI-724) generation CBP / β-catenin antagonists, the efficacy of a bleomycin induction model of IPF in mice (SMC Laboratories, Tokyo, Japan) was demonstrated with the representative compound of the present invention, [3+2]-120A (compound 20). Specifically, oral (po) administration of [3+2]-120A via gastric tube at 100 mg / kg / day (A-low) and 400 mg / kg / day (A-high), initiated on day 7 after bleomycin administration and continued for 2 weeks, was conveniently compared with historical control data and Ashcroft scoring for overall survival with both FDA-approved therapeutic agents for IPF, namely pirfenidone (400 mg / kg / day po) and nintedanib (100 mg / kg / day po). A representative compound of the present invention, [3+2]-120B (compound 11), at a high dose of 400 mg / kg / day was also conveniently compared with historical control data.

[0138] Results. In Figure 5, according to a further non-limiting aspect of the present invention, there was a significant increase in body weight in mice treated with [3+2]-120A (both dose groups) and mice treated with [3+2]-20B (high dose group), as well as in all surviving mice (Figure 6). However, it was shown that approximately 30% of mice still died before day 21 even when treated in this model. Furthermore, significant decreases in lung mass and Ashcroft score (Table 3) were observed in mice treated with [3+2]-120A (both dose groups) and mice treated with [3+2]-120B (high dose group) (Figures 8A-8E) based on histological analysis (Figures 7A-7D). Figures 8A to 8E show the following: a control treated with historical bleomycin saline (8A, "ID:103"); a low dose of [3+2]-120A (8B, "ID:102"); a high dose of [3+2]-120A (8C, "ID:201"); a low dose of [3+2]-120B (8D, "ID:302"); and a high dose of [3+2]-120B (8E, "ID:401"). In all treatment groups, there is a significant reduction in extracellular collagen deposition compared to the historical control treated with bleomycin saline, as determined by Masson's trichrome blue staining. Based on these results, the [3+2] series compounds are effective in a bleomycin-induced model of idiopathic pulmonary fibrosis when administered orally (per os, po).

[0139] [Table 3]

[0140] (Example 20) The efficacy of a representative compound of the present invention, [3+2]-120A, was demonstrated using the STAM(trademark) mouse model of NASH-HCC.

[0141] The efficacy of the proprietary STAM® mouse model for NASH-HCC in mice (SMC Laboratories, Tokyo, Japan) was demonstrated using a representative compound of the present invention, [3+2]-120A (compound 20). Specifically, in ongoing studies, oral (po) administration of [3+2]-120A via gastric tube at doses of 100 mg / kg / day (A-low) and 400 mg / kg / day (A-high) was conveniently compared with vehicle-controlled data for overall survival 4 weeks after treatment. In the vehicle-controlled group, 5 out of 8 mice survived, while in the 100 mg / kg / day (A-low) and 400 mg / kg / day (A-high) doses of [3+2]-120A, 7 out of 8 and 8 out of 8 mice survived, respectively.

[0142] (Example 21) Using an NG / Nga mouse model of atopic dermatitis, we demonstrated the efficacy of a representative compound of the present invention, [3+2]-121A, in reducing TEWL scores and dermatitis scores compared to a vehicle control.

[0143] NG / Nga mouse model of atopic dermatitis: Female NC / Nga mice were obtained from CHARLES RIVER LABORATORIES JAPAN INC. On day 0, the mice were randomized into four groups of eight based on their body weight and dermatitis score. Eight NC / Nga mice were administered topically once daily (100 mg volume) with either a test compound-containing [3+2]-121A (compound 34) ointment or a vehicle control (hydrophilic petrolatum) from day 0 to day 13. At low (100 μM) and high (500 μM) dose levels, representative compound [3+2]-121A significantly reduced TEWL scores and dermatitis scores compared to the vehicle control.

[0144] The representative test substance [3+2]-121A was formulated in hydrophilic petrolatum at low (100uM) and high (500uM) doses (referred to as [3+2]-121A and [3+2]-121B, respectively, in this study). Seven-week-old female NC / Nga mice were used. The first induction of atopic dermatitis was performed three weeks prior to compound administration, in which the hair on the backs and behind the ears of the mice was shaved using clippers and a razor. Then, after the hair on the mice was completely removed with a depilator (Epilat®, Kracie Home Products, Ltd.), 100 mg of Biostir AD® ointment was applied evenly to the shaved dorsal skin and the surface of each ear using a plastic spoon. The second induction of atopic dermatitis was then performed. The mice were shaved of hair on their backs and behind their ears, and then 150 μl of 4% sodium lauryl sulfate solution was applied to their backs and behind their ears using a plastic spoon. This was then dried with a hairdryer (cool air) and allowed to air dry for about 1-2 hours. 100 mg of Biostir AD® ointment was applied evenly to the shaved skin on the backs and the surface of each ear using a plastic spoon. This procedure was repeated twice a week for 3 weeks. Twenty-four atopic dermatitis model mice were sorted into three groups of eight mice each on the morning of day 0 based on the mice's body weight and dermatitis severity score. A vehicle control (hydrophilic petrolatum), [3+2]-121A or [3+2]-121B, was administered topically at a volume of 100 mg once daily from day 0 to day 13. Body weight and food intake were measured once a week on days 0, 7, and 14. The severity of dermatitis was assessed on days 0, 3, 7, 10, and 14. The occurrence of 1) erythema / hemorrhage, 2) scarring / dryness, 3) edema, and 4) exfoliation / erosion was measured on a scale of 0 (none), 1 (mild), 2 (moderate), and 3 (severe). The sum of the individual scores was used as the dermatitis score. TEWL was assessed on days 0 and 14 post-administration. Histological analysis was performed on skin and atrial appendages of the posterior lower neck, fixed in 10% neutral formalin, embedded in paraffin, and thin sections of 3-4 μm thickness, stained with hematoxylin-eosin using Carazzi hematoxylin solution.For the analysis of the skin area, bright-field images of HE-stained sections were randomly recorded at 2- and 4-fold magnifications using a digital camera (DS-Fi3; Nikon). Statistical analysis was performed using Prism Software 6 (GraphPad Software, USA). Statistical analysis was performed using Dunnett's comparison test. The following groups were compared: Group 1 (vehicle) vs. Group 2 ([3+2]-121A) and Group 3 ([3+2]-121B). A P-value < 0.05 was considered statistically significant. Results were expressed as mean ± SD. There was no significant difference in mean body weight on any day during the treatment period between the vehicle group and the treatment groups, demonstrating the lack of toxicity of the treatment (Figure 9). There was no significant difference in food intake per mouse between the vehicle group and the treatment groups (Figure 10).

[0145] Dermatitis severity score: The [3+2]-121A group showed a significant decrease in the dermatitis severity score for the back on days 10 and 14 compared to the vehicle group (Figure 11A back, 11B overall).

[0146] TEWL analysis (Trans-epidermal water loss (TEWL) is the amount of water that evaporates passively through the skin to the external environment by a water vapor pressure gradient across both sides of the skin barrier and is used to characterize the barrier function of the skin): The [3+2]-121A and 121B groups showed a significant decrease in TEWL on day 14 (Figure 12), demonstrating an increase in the barrier function associated with the treatment. Histological analysis: As shown in representative micrographs, a significant decrease in inflammation and inflammatory cell influx was shown in the [3+2]-121A and [3+2]-121B groups (Figures 13A - 13C).

[0147] The present invention, as well as the manner and method of making and using it, are now described in such full, clear, concise, and exact terms as to enable any person skilled in the art to make and use the same. Detailed embodiments of the present invention are described herein for illustrative purposes, but it should be understood that various modifications can be made without departing from the spirit and scope of the invention. Therefore, the invention is not limited to the appended claims.

[0148] All of the above-mentioned U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications referenced herein are incorporated herein by reference.

Claims

1. Formula (Ia): [Formula 1] (Ia) {During the ceremony, R a is hydrogen or -CH 3 and R b is a monocyclic aryl group having 5 to 7 ring members, which optionally has 1 to 2 heteroatoms selected from nitrogen, oxygen or sulfur, and which optionally has one or more substituents selected from the group consisting of halide, cyano, and lower alkyl; R is a phenyl group; a substituted phenyl group having one or more substituents, wherein the one or more substituents are amino, amidino, guanidino, hydrazino, amidazolyl, C 1-4 Alkylamino, C 1-4 Dialkylamino, halogen, perfluoro C 1-4 Alkyl, C 1-4 Alkyl, C 1-3 alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups; benzyl groups; substituted benzyl groups having one or more substituents, wherein the one or more substituents are selected from amino, amidino, guanidino, hydrazino, amidazolyl, C 1-4 Alkylamino, C 1-4 Dialkylamino, halogen, perfluoro C 1-4 Alkyl, C 1-3 or a bicyclic aryl group or a substituted bicyclic aryl having 8 to 11 ring members and optionally having 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur (substituted bicyclic aryl being amino, amidino, guanidino, hydrazino, amidazolyl, C 1-4 Alkylamino, C 1-4 Dialkylamino, halogen, perfluoro C 1-4 Alkyl, C 1-3may have one or more substituents independently selected from alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups; R 2 is hydrogen or -CH 3 and Y is selected from hydrogen, deuterium, or a halogen; W is hydrogen, phosphate, an alkyl acid residue, a fatty acid residue, or X; the alkyl acid residue is obtained by removing an -OH group from a carboxyl group of an alkyl acid, and the carbon atom of the carboxyl group of the alkyl acid residue is bonded to the oxygen atom adjacent to W in formula (Ia); the fatty acid residue is obtained by removing an -OH group from a carboxyl group of a fatty acid, and the carbon atom of the carboxyl group of the fatty acid residue is bonded to the oxygen atom adjacent to W in formula (Ia); X is [chemical 2] [Wherein Z is OR 4 (In the formula, R 4 is hydrogen or C 1 -C 6 alkyl), or Z is an amino acid residue or an amino acid ester residue; the amino acid residue is obtained by removing an H atom from an amine group of an amino acid, and the nitrogen atom of the amine group of the amino acid residue is bonded to the carbon atom of the carboxyl group in X adjacent to Z; the amino acid ester residue is obtained by removing an H atom from an amine group of an amino acid ester, and the nitrogen atom of the amine group of the amino acid ester residue is bonded to the carbon atom of the carboxyl group in X adjacent to Z; and n is 1 or 2; L is -CH 2 -, -CF 2 - or -C(CH 3 ) 2 - and Q is a 5- or 6-membered nitrogen-containing heteroaryl substituted with 0-2 substituents; [C3] wherein A, B, and D are independently selected from O, S, N, or —CH; Z 1 and Z 2 is hydrogen, deuterium, halogen, C 1 -C 4 Alkyl, -OH, -OC 1 -C 6 Alkyl, [C4] (In the formula, R 1 , R 2 and R 3 is hydrogen, C 1 -C 6 Alkyl or C containing one or more -OH 1 -C 6 alkyl); Z 3 is the following (i) hydrogen, (ii) halogens, (iii) a directly bonded aryl, heteroaryl, cycloalkyl, or heterocycloalkyl; (iv) an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl bonded to -NH-; (v)-OC 1 -C 3 an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl bonded to an alkyl; (vi)-NHC 1 -C 3 an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl bonded to an alkyl; (vii) a cycloalkyl or heterocycloalkyl attached to a nitrogen atom; (viii)-NHC 1 -C 4 Alkyl, or (ix) -N(C 1 -C 4 Alkyl) 2 each of (iii) to (ix) is selected from hydrogen, deuterium, halogen, C 1 -C 4 Alkyl, C 1 -C 3 Haloalkyl, -OH, -OC 1 -C 6 Alkyl, -OC 1 -C 6 Alkyl-C(O)NH-OH, -NH 2 , -C(O)NH-C 1 -C 6 Alkyl-heteroaryl, -NHC(O)C 1 -C 6 substituted with 0 to 4 substituents independently selected from alkyl-C(O)NH—OH, heteroaryl, cycloalkyl, or heterocycloalkyl; or a pharma- ceutically acceptable salt thereof.

2. The alkyl acid residue or the fatty acid residue is [C5] (wherein m is 1 to 14); [C6] 2. The compound of claim 1 , selected from:

3. 3. The compound of claim 1 or 2, wherein R is a bicyclic aryl selected from naphthyl, quinolinyl, isoquinolinyl, quinoxaline, phthalazine, quinazoline, cinnoline, naphthyridine, or substituted variants thereof.

4. The compound has the formula (Ib): [C7] (Ib) (In the formula, X 1 and X 2 is independently selected from N, or —CH; R 2 4. The compound according to any one of claims 1 to 3, wherein Y, W, L and Q are as defined in claim 1.

5. L is -CH 2 - and Q, [C8] wherein A, B, and D are independently selected from O, S, N, or —CH; Z 3 is as defined in claim 1.

6. A is -CH, B is N, and D is O(Z 3 -isoxazole-), W is hydrogen, phosphate or phosphoric acid salt, an alkyl acid residue as defined above, a fatty acid residue as defined above, or X, and X is [C9] [Wherein Z is OR 4 (In the formula, R 4 is hydrogen or C 1 -C 6 6. The compound according to claim 5, wherein Z is an alkyl group, or Z is an amino acid residue or an amino acid ester residue, and n is 1 or 2.

7. Z 3 is selected from aryl or heteroaryl, each of the aryl and heteroaryl being hydrogen, deuterium, halogen, C 1 -C 4 Alkyl, C 1 -C 3 Haloalkyl, -OH, -OC 1 -C 6 Alkyl, -OC 1 -C 6 Alkyl-C(O)NH-OH, -NH 2 , -C(O)NH-C 1 -C 6 Alkyl-heteroaryl, -NHC(O)C 1 -C 6 7. The compound of claim 6, substituted with 0 to 4 substituents independently selected from alkyl-C(O)NH-OH, heteroaryl, cycloalkyl, or heterocycloalkyl.

8. Z 3 However, hydrogen, deuterium, halogens, C 1 -C 4 Alkyl, C 1 -C 3 Haloalkyl, -OH, -OC 1 -C 6 8. The compound of claim 7, selected from aryl or heteroaryl substituted with 0-4 substituents independently selected from alkyl, or heterocycloalkyl attached to the nitrogen.

9. The compound is [C10] [ka] [ka] 9. The compound of claim 8, wherein

10. A composition, or pharmaceutical composition, comprising a compound according to any one of claims 1 to 9 and a pharma- ceutically acceptable carrier.

11. A pharmaceutical composition for treating a disease or disorder mediated by CREB binding protein (CBP) / β-catenin signaling, comprising a compound according to any one of claims 1 to 10 in an amount sufficient to inhibit CBP / catenin signaling and / or enhance p300 / catenin mediated signaling.

12. The pharmaceutical composition of claim 11 , wherein the amount of the compound comprises a therapeutically effective amount.

13. In the compound, W is X, and X is [C11] [In the formula, Z is OR 4 (In the formula, R 4 is hydrogen or C 1 -C 6 alkyl), or Z is an amino acid residue or an amino acid ester residue as defined above; The pharmaceutical composition according to claim 11 or 12, wherein n is 1 or 2.

14. In the compound, X is [C12] [Wherein Z is OR 4 and R 4 is hydrogen or C 1 -C 6 The pharmaceutical composition according to any one of claims 11 to 13, wherein n is alkyl, or Z is the amino acid residue or the amino acid ester residue, and n is 1 or 2.

15. The pharmaceutical composition of any one of claims 11 to 14, wherein the disease or disorder comprises one or more of fibrosis, cancer, a neurological condition, a metabolic disorder, a skin condition and ageing.

16. 16. The pharmaceutical composition of claim 15, wherein the metabolic disorder comprises one or more of diabetes and / or fatty liver disease.

17. 17. The pharmaceutical composition of claim 16, wherein the fatty liver disease comprises one or more of alcoholic fatty liver (ALD), non-alcoholic fatty liver (NAFLD), and / or non-alcoholic steatohepatitis (NASH).

18. 16. The pharmaceutical composition of claim 15, wherein the fibrosis is pulmonary, hepatic, renal, cardiac, endometrial, cutaneous or systemic fibrosis.

19. 19. The pharmaceutical composition of claim 18, wherein the fibrosis comprises fibrosis in tissue of a SARS-CoV-2 (COVID-19) patient.

20. 16. The pharmaceutical composition of claim 15, wherein treating cancer comprises administering a CBP / β-catenin antagonist in combination with or as adjunctive therapy to one or more of the following: cytotoxic and / or directed chemotherapy, and / or radiotherapy, and / or immunotherapy including checkpoint inhibition, chimeric antigen receptor (CAR-T) and / or CAR-NK.

21. 16. The pharmaceutical composition of claim 15, wherein the neurological condition comprises one or more of Huntington's disease (HD), Parkinson's disease (PD), Alzheimer's disease (AD), multiple sclerosis (MS), and / or amyotrophic lateral sclerosis (ALS), muscular dystrophy (MD), and / or spinal muscular atrophy (SMA).

22. 16. The pharmaceutical composition of claim 15, wherein the skin condition comprises one or more of atopic dermatitis, psoriasis, acne, fibrosis, wounds, scars, burns, sun or U.V. damage, diabetic ulcerations, chronic ulcerations, and / or alopecia.

23. 23. The pharmaceutical composition of claim 22, wherein W is said alkyl acid residue or said fatty acid residue and administration comprises topical or transdermal administration.

24. 11. A cosmetic composition for treating a skin condition, comprising a cosmetically effective amount of a compound according to any one of claims 1 to 10, wherein W is said alkyl acid residue or said fatty acid residue.

25. 25. The cosmetic composition of claim 24, wherein the skin condition comprises one or more aging skin conditions selected from wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of color, loss of elasticity, thinning hair, loss of color, scarring, acne, sun damage, hair loss, loss of hair color, reduced cuticle growth, and reduced nail growth.

26. A method for the efficient synthesis of drugs, comprising the use of an intermediate 2-propynyl-compound of formula (IIa) in the penultimate or last reaction step under GMP conditions to form an isoxazole derivative by 3+2 cycloaddition, wherein the step of preparing the isoxazole derivative comprises the use of an intermediate 2-propynyl-compound of formula (IIa) in the penultimate or last reaction step, prior to any formation of a final pharma- ceutically acceptable salt, phosphate or phosphoric acid salt, of formula (IIa): [C13] (IIa) [In the formula, R a is hydrogen or -CH 3 and R b is a monocyclic aryl group having 5 to 7 ring members, which optionally has 1 to 2 heteroatoms selected from nitrogen, oxygen or sulfur, and which optionally has one or more substituents selected from the group consisting of halide, cyano, and lower alkyl; R is a phenyl group; a substituted phenyl group having one or more substituents, wherein the one or more substituents are amino, amidino, guanidino, hydrazino, amidazolyl, C 1-4 Alkylamino, C 1-4 Dialkylamino, halogen, perfluoro C 1-4 Alkyl, C 1-4 Alkyl, C 1-3 alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups; benzyl groups; substituted benzyl groups having one or more substituents, wherein the one or more substituents are selected from amino, amidino, guanidino, hydrazino, amidazolyl, C 1-4 Alkylamino, C 1-4 Dialkylamino, halogen, perfluoro C 1-4 Alkyl, C 1-3 or a bicyclic aryl group having 8 to 11 ring members and optionally having 1 to 3 heteroatoms selected from nitrogen, oxygen, or sulfur; R 2 is hydrogen or -CH 3 and Y is selected from hydrogen, deuterium, or a halogen; W is an alkyl acid residue, a fatty acid residue, or X; the alkyl acid residue is obtained by removing an -OH group from a carboxyl group of an alkyl acid, and the carbon atom of the carboxyl group of the alkyl acid residue is bonded to the oxygen atom adjacent to W in formula (IIa); the fatty acid residue is obtained by removing an -OH group from a carboxyl group of a fatty acid, and the carbon atom of the carboxyl group of the fatty acid residue is bonded to the oxygen atom adjacent to W in formula (IIa); X is [C14] (Wherein, Z is OR 4 and R 4 is hydrogen or C 1 -C 6 alkyl, or Z is an amino acid residue or an amino acid ester residue; the amino acid residue is obtained by removing an H atom from an amine group of an amino acid, and the nitrogen atom of the amine group of the amino acid residue is bonded to the carbon atom of the carboxyl group in X adjacent to Z; the amino acid ester residue is obtained by removing an H atom from an amine group of an amino acid ester, and the nitrogen atom of the amine group of the amino acid ester residue is bonded to the carbon atom of the carboxyl group in X adjacent to Z; and and n is 1 or 2), to prepare a compound according to any one of claims 6 to 9.

27. 27. The method of claim 26, wherein the last or penultimate step carried out under GMP conditions is preceded by one or more reaction steps under non-GMP conditions as part of an overall reaction scheme for preparing an isoxazole derivative.

28. Formula (IIa): [C15] (IIa) {During the ceremony, R a is methyl or hydrogen; R bis a monocyclic aryl group having 5 to 7 ring members, which optionally has 1 to 2 heteroatoms selected from nitrogen, oxygen or sulfur, and which optionally has one or more substituents selected from the group consisting of halide, cyano, and lower alkyl; R is a phenyl group; a substituted phenyl group having one or more substituents, wherein the one or more substituents are amino, amidino, guanidino, hydrazino, amidazolyl, C 1-4 Alkylamino, C 1-4 Dialkylamino, halogen, perfluoro C 1-4 Alkyl, C 1-4 Alkyl, C 1-3 alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups; benzyl groups; substituted benzyl groups having one or more substituents, wherein the one or more substituents are selected from amino, amidino, guanidino, hydrazino, amidazolyl, C 1-4 Alkylamino, C 1-4 Dialkylamino, halogen, perfluoro C 1-4 Alkyl, C 1-3 or a bicyclic aryl group having 8 to 11 ring members and optionally having 1 to 3 heteroatoms selected from nitrogen, oxygen, or sulfur; R 2 is hydrogen or -CH 3 and Y is selected from hydrogen, deuterium, or a halogen; W is an alkyl acid residue, a fatty acid residue, or X; the alkyl acid residue is obtained by removing an -OH group from a carboxyl group of an alkyl acid, and the carbon atom of the carboxyl group of the alkyl acid residue is bonded to the oxygen atom adjacent to W in formula (IIa); the fatty acid residue is obtained by removing an -OH group from a carboxyl group of a fatty acid, and the carbon atom of the carboxyl group of the fatty acid residue is bonded to the oxygen atom adjacent to W in formula (IIa); X is, [C16] [In the formula, Z is OR 4 (In the formula, R 4 is hydrogen or C 1 -C 6 alkyl), or Z is an amino acid residue or an amino acid ester residue; the amino acid residue is obtained by removing an H atom from an amine group of an amino acid, and the nitrogen atom of the amine group of the amino acid residue is bonded to the carbon atom of the carboxyl group in X adjacent to Z; the amino acid ester residue is obtained by removing an H atom from an amine group of an amino acid ester, and the nitrogen atom of the amine group of the amino acid ester residue is bonded to the carbon atom of the carboxyl group in X adjacent to Z; and n is 1 or 2}.

29. A pharmaceutical composition for enhancing vaccine efficacy comprising a compound according to any one of claims 1 to 10 in an amount sufficient to inhibit CBP / β-catenin mediated signaling and / or enhance p300 / catenin mediated signaling, said enhancing vaccine efficacy being effected by administering said amount of compound to a subject prior to vaccination and / or during vaccination and / or after vaccination.

30. 30. The pharmaceutical composition of claim 29, wherein the amount of the compound comprises a therapeutically effective amount.

31. The pharmaceutical composition of claim 29 or 30, wherein enhancing vaccine efficacy comprises one or more of: increasing the level of vaccine antigen-specific antibodies; increasing the percentage of protection generated; increasing the number and / or persistence of differentiated memory T-cells; and / or increasing the duration of protection.

32. The pharmaceutical composition according to any one of claims 29 to 31, wherein inhibiting CBP / β-catenin mediated signaling and / or enhancing p300 / catenin mediated signaling comprises one or more of: metabolic maintenance of post-division cellular asymmetry of activated T cells in a subject; enhancing antigen-specific immunity by increasing the number and / or persistence of differentiated memory T cells; and / or enhancing presentation of antigens to T cells by antigen presenting cells to enhance cooperation between the innate and adaptive immune systems.

33. The pharmaceutical composition according to any one of claims 29 to 32, wherein the vaccination comprises the administration of an antiviral vaccine.

34. The pharmaceutical composition according to any one of claims 29 to 33, wherein the vaccination comprises the administration of an anti-viral vaccine selected from influenza, SARS, SARS-CoV-2, HPV-A, HPV-B, and / or shingles.

35. The pharmaceutical composition of any one of claims 29 to 34, wherein the subject is a human aged between 55 and 75 years, 55 and 85 years, ≧50 years, ≧60 years, or ≧65 years.

36. The pharmaceutical composition according to any one of claims 29 to 35, wherein administration comprises administration as an initiator before vaccination; and / or simultaneous administration with vaccination; and / or administration after the first vaccination or simultaneous administration.

37. 13. A method of treating a disease or disorder comprising administering to a non-human animal having a disease or disorder mediated by CREB binding protein (CBP) / β-catenin signaling an amount of a compound according to any one of claims 1 to 10 sufficient to inhibit CBP / catenin signaling and / or enhance p300 / catenin mediated signaling.

38. 13. A method for enhancing vaccine efficacy, comprising administering to a non-human subject an amount of a compound according to any one of claims 1 to 10 sufficient to inhibit CBP / β-catenin mediated signaling and / or enhance p300 / catenin mediated signaling prior to vaccination and / or during vaccination and / or after vaccination.

39.

17. A compound represented by the formula: